DEBRISOQUINE POLYMORPHISM IN PALESTINIANS IAbu AI-Kahia M, ~Roustom R, 3Siegmund W, sZschiesche M and 3Franke G.
Grapefruit juice may considerably increase the systemic bioavailability of drugs as felodipine and nifedipine. This food-drug interaction has potential practical importance because citrus juices are often consumed at breakfasttime when drugs are often taken. It is likely that a plant flavonoid in grapefruit juice, naringenin, is responsible for this effect (inhibition of cytochrome P-450 enzymes in the liver or in the small intestinal wall). Ethinylestradiol (EE2), the estrogen of oral contraceptive steroides, shows a high first-pass-metabolism in vivo. Therefore, the purpose of this study is to test the interaction between grapefi-uite juice and EE 2, The area under the serum concentration-time curve (AUC0_24h) ofEE 2 was determined in a group of young healthy women (n = 13) on day 4 + 1 ofmenstruale cycle. To compare intraindividually, the volunteers were randomly allocated to two test days. The female volunteers took 50 lag EE 2 together with either 200 ml of herb tea or with the same amount of grapefruit juice (content of naringenin 887 mg/1). Furthermore, on the day of testing the women drank 4 times 200 ml of the corresponding fluid every three hours up to four times. The AUC0.24 h of EE 2 amounts to 1110.5 + 637.7 pg x mI-1 x h after the administration of the drug with grapefruit juice; that means 28 % higher in comparison to 868 0 + 490.0 pg x m1-1 x h after concomitant intake of tea. Also, the mean Cmax-value increases to 37 %, p _< 0.01 (117.5 + 53.2 pg x m1-1 and 85.5 + 32.9 pg x m1-1, respectively). This result shows that the systemic bioavailability ofEE 2 increases after intake of the drug with grapefruit juice. The extent of this effect is lower than the extent of known interindividual variability. Procarbazine is a tumourstafic agent widely used m Hodgin's disease, non-Hodgldn's lymphomas and mmours of brain and lung. Procarbazine is an inactive prodrug which is converted by a cytochrome P 450 mediated reaction to its active metabolites, in the first step to azoprocarbazine. The kinetics of both procarbazine and azoprocarbazine is not described in humans up to now. On 10 turnout patients we have investigated the plasma kinetics of both procarbazine and azoprocarbazine after oral adminislxation of 300 mg procarbazine in form of capsules and drink solution, respectively. A HPLC method with UV-detection (254 nrn) and detection limits of 50 and 150 ng/ml was developed for procarbazine and azoprocarbazine respectively. After both the capsules and drink solution the parent drug could be detected in plasma only for 1 h. In contrast the tl/2 of terminal elimination of azoprocarbazine was estimated in the range of 0,9 to 6,5 h with a mean of 2,96 h -2 + 1,46 h. The AUC of procarbazine was less than 5 % of that of azoprocarbazine. Cma x values of azoprocarbazine were determined in the range of 1,3 to 6,l gg/ml. In comparison to the drink solution we determined on the basis of the plasma levels of azoprocarbazine a bioavailability of the therapeutic used procarbazine capsules of 93,1 + 26,3 %.
Prostaglandin E1 (PGE1) is used for the treatment of patients with peripheral arterial disease, and probably effective due to its vasodilator and antiplatelet effects. L-arginine is the precursor of endogenously synthesized nitric oxide (NO). In healthy human subjects, Larginine also induces peripheral vasodi]ation and inhibits platelet aggregation due to an increased NO production. In the present study the influence of a single intravenous dose of L-arginine (30g, 60 min) or PGE1 (40p.g, 60 min) on blood pressure, peripheral hemodynamics (femoral artery Duplex sonography), and urinary NO3-and cGMP excretion rates was assessed in ten patients with peripheral arterial disease (Fontaine III -IV). Blood flow in the femoral artery was significantly increased by L-arginine by 68% (p < 0.01), and by PGE1 by 25% (p < 0.05). L-arginine more strongly decreased systolic and diastolic blood pressure than PGE1. Plasma arginine concentration was increased 4-fold by L-arginine, but unaffected by PGE1. Urinary excretion of NO3-increased by 118% after L-arginine (p < 0.05), and by 78% after PGE1 (p = n.s.). Urinary cGMP excretion increased by 76% after L-arginine and by 43% after PGEI (each p = n.s.). We conclude that intravenous L-arginine decreases peripheral arterial resistance, resulting in enhanced blood flow and decreased blood pressure in patients with peripheral arterial disease. These effects were paralleled by increased urinary NO3-excretion, indicating that systemic NO production was enhanced by the infusion. Increased NO3-excretion may be a sum effect of NO synthase substrate provision (L-arginine) and increased shear stress (PGE1 and L-arginine).
Institutes of Clinical Pharmacology and *Angiology, Medical School, Hannover, Germany.
A7 SYSTEMIC AND PULMONARY HAEMODYNAMIC EFFECTS OF L-ARGININE 1N PATIENTS WITH CORONARY HEART DISEASE AND PRIMARY PULMONARY HYPERTENSION.
Rainer H. B6ger, Stefanie M. Bode-B6ger, Andreas Miigge*, Marius H6per**, Doris Heinzel, J/irgen C. Fr61ich.
It is welI established that the endothelial EDRF/NO-mediated relaxing mechanism is impaired in atherosclerotic and in hypertensive arteries. Recently it was suggested that primary pulmonary hypertension might be another disease in which the endothelial EDRF/NO pathway is disturbed. We tested the hypothesis that intravenous administration of L-arginine (L-ARG), the physiological precursor of EDRF/NO, stimulates the production of NO, subsequently increasing plasma cGMP levels and reducing systemic and / or pulmonary vasular resistance, in patients with coronary heart disease (CHD; n = 15) and with primary pulmonary hypertension (PPH; n = 5). L-ARG (30g, 15 min) or placebo (NaC1) was infused in CHD patients, and L-ARG was infused in PPH patients undergoing cardiac catheterization. Mean aortic (Pao) and pulmonary (Ppul) arterial pressures were continuously monitored. Cardiac output (CO; by thermodilution), and total peripheral resistance (TPR) were measured before and during the infusions. Plasma cGMP was determined by RIA. In CHD patients, Pao decreased from 87.2 + 4.9 to 81.8 + 5. mm Hg during L-ARG (p<0.05), whereas Ppul was unchanged. TPR decreased from 1008.9 -+ 87.9 to 845.0 +81.7 dyne sec cm -5 during L-ARG administration (p<0.01). CO significantly increased during L-ARG (from 7.3 + 2.8 to 8.1 + 0.9 1/min, p<0.05). Placebo did not significantiy influence any of the haemodynamic parameters, cGMP slightly increased by 12.2 + 9.6% during L-ARG, but slightly decreased during placebo (-12.3 +9.2 %)(p < 0.05 for L-ARG vs. placebo). In PPH patients, L-ARG induced no significant change in Pao, TPR, and CO. Mean Ppul was 63.4 + 8.8 mm Hg at the beginning of the study, but was only slightly reduced by L-ARG to 55.0 + 12,3 mm Hg (p = n.s.). Plasma cGMP was not affected by L-ARG in these patients. We conclude that L-ARG stimulates NO production and induces vasorelaxation in CHD patients, but not in patients with primary pulmonary hypertension. Thus, the molecular defects underlying the impaired NO foimation may be different m both diseases. Institutes of Clinical Pharmacology, *Cardiology, and **Pneumology, Medical School, Hannover, Germany.
A8 INCREASED PROSTACYCLIN PRODUCTION DURING SUB-MAXIMAL EXERCISE IN TRAINED AND UNTRAINED SUB-JECTS: EFFECT OF LOW-DOSE ASPIRIN ADMINISTRATION.
Rainer H. B~ger, Stefanie M. Bode-B6ger, Dimitrios Tsikas, J0rgen C. Fr61ich.
The influence of submaximal exercise on the urinary excretion of 2,3-dinor-PGFlc, (the major urinary prostacyclin metabolite), 2,3-dinor-TXB2 (the major urinary thromboxane A2 metabolite), and PGE2(originating from the kidney), and on platelet aggregation was assessed in 6 untrained and 10 endurance-trained male subjects before and after 7 days of 50 rag/day of aspirin. Urinary 2,3-dinor-TXB2 excretion was significantly higher in the athletes at rest (p < 0.05). Submaximal exercise increased urinary 2,3-dinor-6-keto-PGFl~ excretion without affecting 2,3-dinor-TXB2 or PGE2 excretion or platelet aggregation. Aspirin treatment induced an -80% inhibition of platelet aggregation and 2,3-dinor-TXB2 excretion in both groups. However, urinary 2,3-dinor-6-keto-PGFl~ was inhibited by only 24% in the untrained, but by 51% in the trained group (p <0.05). Urinary PGE2 was unaffected by aspirin in both groups, indicating that cyclooxygenase activity was not impaired by a systemic aspirin effect. After low dose aspirin administration, the same selective stimulatory effect of submaximal exercise on urinary 2,3-dinor-6-keto-PGFl~ excretion was noted in both groups as before. The ratio of 2,3-dinor-6-ketoPGFld2,3-dinor-TXB2 was increased by exercise; this effect was potentiated by aspirin (p < 0.05). Our results suggest that the stimulatory effect of submaximal exercise on prostacyclin production is not due to an enhanced prostacyclin endoperoxide shift from activated platelets to the endothelium, but rather the result of endothelial prostacyclin synthesis activation from endogenous precursors. 50 mg/day of aspirin potentiates the favorable effect of submaximal exercise on endothelial prostacyclin production by selectively blocking platelet cyclooxygenase activity. Institute of Clinical Pharmacology, Medical School, Hannover, Germany.
Soluble guanylyl cyclases (GC-S) are heterodimeric hemeproteins consisting of two protein subunits (70 KDa, 82 KDa). The enzyme is activated by nitric oxide (NO) and catalyzes the formation of the signal molecule "cGMP" (cyclic guanosine-3'S'-monophosphate) from GTP. Numerous physiological effects of cGMP are already very well characterized. However, detailed insights in the NO-activation mechanism of this enzyme have been described to date only in a hypothetical model (1). Recently, this concept was supported by experimental data using sitedirected mutagenesis to create a NO-insensitive soluble guanylyl cyclase mutant (2). It is generally accepted that the prostethic heine-group plays a crucial role in the activation mechanism of this protein. Nonetheless, some interesting questions with regard to structure and regulation of soluble guanylyl cyclases still need to be uncovered (e.g. activation with other free radicals, such as carbon monoxide). Since this kind of studies is limited so far by isolating large quantities of a biologically active enzyme with conventional purification techniques, the recombinant protein was expressed in the baculovirus / insect cell system. We describe here the construction and characterization of recombinant baculoviruses, harboring the genes that encode both protein subunits of the soluble guanylyl cyclase. Insect cells infected with these recombinant baculoviruses produce between 20-30% (as related to total cell protein) of functional soluble guanylyl cyclase. Positive infection was monitored as a change in morphology of the cells and by production of the respective recombinant viruses detected by polymerase-chain-reaction (PCR). So far examined, the recombinant enzyme exhibits similar physicochemical characteristics as the "natural" protein. Exogenous addition of several heme analogues to the infected cells is able to either stimulate or inhibit the enzymatic activity of GC-S. We are confident to purify milligram amounts of the recombinant protein in the near future. PET studies of myocardial pharmacology have principally concerned the sympathetic nervous system and u'acers have been developed to probe the integrity of both pre-and post-synaptic sites. The sympathetic nervous system plays a crucial role in the control of heart rate and myocardial contractility as well in the conlrol of the coronary circulation. Alterations of this system have been implicated in the pathophysiology of a number of .cardiac disorders, in particular, heart failure, ventricular arrhythmogenesis, coronary artery disease, idiopathic dilated and hypertrophic cardiomyopathy. Several beta blockers have been labelled with carbon-ll for imaging by PET. The most promising of these is CGP 12177 which is a non-selective beta adrenoceptor anatagonist particularly suited for PET studies due to its high affinity and low lipophilicity, thus enabling the functional receptor pool on the cell surface to be studied. Studies in our institution in a group of young healthy subjects have yielded Bmax values of 10.4_+1.7 pmol/g myocardium. These data are consistent with literature values of Bmax for beta adrenoceptors in human ventricular myocardium determined by a variety of in vitro assays. A recent study in patients with hypertrophic cardiomyopathy has shown that myocardial beta adrenoceptor density is decreased by approximately 25-30% relative to values in normal subjects. The decrease in receptor density occurs in both hypertrophied and nonhypertrophied portions of the left ventricle. These data are consistent with the hypothesis that sympathetic overdrive might be involved in the phenotypic expression of hypertrophic cardiomyopathy. A further decrease of myocardial beta adrenoceptor density (to levels well below 76_5-7.7 pmol/g) has been observed in those patients with hypertrophic cardiomyopathy who procede to ventricular dilatation and heart failure.
MRC Clinical Sciences Centre, Hammersmith Hospital, Du Cane Road, London W12 ONN, (UK).
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CYTOCHROME P4501A1 (CYPIA1) AND GLUTATHIONE-S-TRANSFERASE IJ (GSTM1 type A and B): ASSOCIATION TO LUNG CANCER SUSCEPTIBILITY
I. Cascorbi, J. Brockm611er, R. Kerb, P. Mrozikiewicz, E. MOiler, and I. Roots CYP1A1 hydroxylates polycyclic aromatic hydrocarbons such as benzo(a)pyrene occurring e.g. in cigarette smoke. Two hereditary mutations are discovered: ml, a T to C transition 1,194 bp downstream of exon 7; m2, located at position 4,889 in exon 7 representing an A to G transition resulting an isoleucine to valine substitution in the heme-binding region. Recently we could demonstrate in Caucasians that carriers of the m2-mutation possess an increased risk towards lung cancer (Drakoulis et aL Clin.lnvestig. 72:240,1994) , whereas the ml-mutation shows no such association. The Phasg-II enzyme GSTM1 catalyses the conjugation of glutathione to electrophilic compounds such as products of CYP1AI. GSTM1 is absent in 50.9% of the Caucasian population due to base deletions in exon 4 and 5 of the gene. We found no contrariety in the GSTM1 distribution, including frequencies of type A (p.) and type B (V) among lung cancer patients (odds ratio = 1.01, n = 117; Cancer Res. 53:1004 Res. 53: ,1993 .
149 lung cancer patients and 408 reference patients were investigated for mutations of CYPIA1 and GSTM1 by allele-specific PCR and RFLP. A statistically significant higher risk for lung cancer among carriers of the m2-trait was found (odds ratio = 2.63, P = 0.001). Interestingly, amid lung cancer, m2-alleles were less often linked to ml than in controls (odds ratio = 9.50, 95%-confidence limits = 1.50 -99.7, P = 0.0054). However, the frequency of CYPIA1 mutations did not differ among active and defective GSTM1 types. Consequently, we could not confirm in the Caucasian population the synergistic effects of CYPIA1 mutations (especially m2) and deficient GSTM1 as combined susceptibility factors for lung cancer as described among the Japanese (Cancer Res. 55:2994 ,1993 
J. Chemnitz, A. yon zur M~hlen and T.H. Sch~rmeyer
In healthy subjects the effect of gastrointestinal hormones like somatostatin and glucagon on splanchnic hemodynamics is not well defined due to the invasiveness of the direct measurement of e.g. portal vein (PV) wedged pressure.
Methods : Now, we applied Duplex sonography (3.5 M~z) and color coded flow mapping to compare the effects of ocreotide (i00 ~g sc), a long acting somatostatin agonist, and glucagon (i mg iv) on the hemodynamics of the PV, superior mesenteric artery (SMA) and common hepatic artery (HA) in 14 healthy volunteers (13 G,I Q; 25 ± 2y; x ± sem).
Results
:
Basal values of PV flow (12.9 ± 0.8 cm/s), PV flow volume (549 ± 50 ml/min), SMA systolic (sF: 195 ± 13 cm/s) and diastolic flow (dF: 28 ± 4 cm/s), SMA Pourcelot index (PI) (0.86 ± 0.01), HA sF (80 ± 8 cm/s) and dF (19 ± 1 cm/s) and HA PI (0.75 ± 0.01) well agreed with previously reported results. within 15 min ocreotide resulted in a decrease of SMA sF (-32 ± 4%) SMA dF (-31 ± 4%), HA sF (-18 ± 5%) and HA dF (-24 ± 7 %). Maximum drop of PV flow (-33 ± 3%) and flow volume (-34 ± 7%) occurred at 30 min. All effects diminished at 60 min. No significant change of vessel diameter and PI was seen. 5 min following its application glucagon caused a highly variable, only short lasting increase of PV flow volume (+51 ± 18%) and SMA dF (+49 ± 17%). HA Fd (+14 ± 4%) showed a tendency to rise (ns Pectanginal pain and signs of silent myocardial ischemia frequently occur in hypertensives, even in the absence of coronary artery disease (CAD) and/or left ventricular hypertrophy, probably due to a reduced coronary flow reserve. Since the oxygen extraction of the heart is nearly maximal during rest, increases of oxygen demand cannot be balanced by increases of myocardial perfusion: To assess the frequency of ischemic type ST-segment depressions in this patients and to determine the influence of heart rate (HR) and blood pressure (BP), simultaneous 24 h Hoher-and 24 h ambulatory BP monitoring were performed in 18 hypertensives (age 43 -71 years, 9 f, 9 m) without CAD before and after four weeks on therapy with the 13 -blocker betaxolol. 25 episodes of significant ST-segment depressions (>0.1 mV,> 1 min) of a total length of 470 min could be demonsu'ated in 9/18 patients (50%) without antihypertensive therapy_ Systolic BP significantly increased from 139 + 13.9 mmHg (mean + SD, p < 0.05) 60 min before to a maximum of 191 + 44.5 mmHg during the ischemic episodes, HR and rate-pressure product (RPP) increased from 76 + 6.3 min -t and 100.6 + 20.9 mmHg x rain -t x 102 to 138 _+ 16.8 min-: and 230.4 + 88.9 mmHg x min -1 x 102 (p < 0.05). The extent of ST-segment depressions significantly correlated with HR and RPP (p < 0.05). Drug therapy with 10 -20 mg/d betaxolol for 4 weeks significantly decreased mean HR, systolic' and diastolic BP (p < 0.05). 6 ischemic episodes of a total length of 38 min were recorded only in 4 of 15 hypertensives (26.7 %; p < 0.05; X2-test).
In conclusion, increases of HR and systolic BP seem to be the most important factors which induce myocardial ischemia in hypertensives without CAD. As silent ischemia is a independent risk factor for sudden cardiac death and other cardiac events, specific antihypertensive therapy should not only be aimed to normalize blood pressure, but should also address reduction of ischemic episodes as demonstrated here. Phosphodiesterase inhibitors exert their positive inotropic effects by inhibiting cAMP degradation and increasing the intracellular calcium concentration in cardiomyocytes. An identical phosphodiesterase type 1I[ has been demonstrated in platelets and vascular smooth muscle cells. We studied the influence ofpiroximone on platelet function in vitro and ex vivo and the hemodynaimc effects of a bolus application of piroximone in patients with severe heart failure (NYHA III-IV) using a Swan -Ganz-Catheter. In order to study the influence ofpiroximone on platelet function in vitro, platelet rich plasma from healthy volunteers was incubated with piroximone (10-100 ~tmol/l) from 1 minute to 2 hottrs and aggregation was induced by addition of ADP. For the ex vivo experiments platelet rich plasma was obtained from patients, who received piroximone in doses of 0.25, 0.5, 1.0 or 2.0 mg/kg bw. Blood samples were drawn immediately before and 30, 60, 90, 120 and 240 minutes after bolus application. The ADP-induced platelet aggregation was inhibited time-and dosedependently. The IC50 value for piroximoue in vitro amounted to 67 +14 omol/1. In the ex vivo experiments the maximal inhibition of ADP-induced aggregation was obtained in PRP from patients who had received 2 mg/kg bw piroximune 60 minutes before. The admitdstration ofpiroximone resulted in a marked hemodynamic improvement with a dose-dependent increase in cardiac index and decreases in pulmonary artery pressure and resistance. However, no data concerning pulmonary extraction of dobutamine (DBU) exist. Patients admitted to the surgical ICU who were receiving DBU and had pulmonary and arterial catheters in place were eligible. A set of paired blood samples were obtained for DBU concentrations simultaneously from the arterial (Ca) and distal port (Cv) of the pulmonary artery catheter after at least a 30 rain infusion at a constant rate. DBU concentrations were determined by HPLC (CV = 9% at concentrations of 50 -500 ng/mL). Total clearance (Cl) was calculated by Dose/Css, pulmonary extraction by (CvCa)/Cv.
Eleven patients (4M, 7F), 64 + 16 years, 71 + 24 kg were studied.
Four patients had ARDS. DBU was administered at 7.8 + 5.4 ~Ig/kg/min for 8.5 + 10.5 hrs before DBU concentrations were obtained. Ca averaged 172 + 178 ng/mL, while Cv was 178 + 187 ng/mL (ns by t-test). DBU total clearance averaged 82 +_ 63 mL/kg/min. The absolute % extraction was 3.6 + 23.0. Correlation between % extraction and Cv was r = 0.003. The % extraction for most patients could be explained by the coefficient of variation of the assay.
A wide range of DBU concentrations were seen. The pulmonary extraction of DBU is low suggesting a minimal first-pass elimination of drug through the lung.
The
Ohio State University, College of Pharmacy, Columbus, OH 43210, USA.
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131-and 1~2-adrenergic contributions responses in healthy man C. de Mey, K. Erb, R. Butzer, G.G. Belz
to 13-adrenergic inodilatory
The responses to 10 min iv. infusions of the 131-and 132-adrenoceptor agonist isoprenalin (ISO) and the 132-(and c~-) adrenoceptor agonist adrenalin (ADR) at constant rates of 1 IJg/min were evaluated noninvasively after pretreatment (pre-Tr) with placebo (PL), 100 mg of the 131-selective adrenoceptor antagonist talinolol (TAL) and 80 mg of the non-selective 13-antagonist propranolol (PRO) in 12 healthy subjects. The following were analysed: heart rate (HR, bpm), pre-ejection time (PEP, ms), ejection time (VET, ms), HR-corrected electromechanical systole (QS2c, ms), impedance-cardiographic estimates of stroke volume (SV, ml), cardiac output (CO, I/min) and peripheral resistance (TPR, dyn.s.cm -5) calculated from CO and mean blood pressure (SBP and DBP according to auscultatory Korotkoff-I and -IV sounds This indicates that 1) about half the rise of HR and CO and half the shortening of PEP is 131-respectively 1~2-determined, 2) that predominant 132-adrenergic responses, whilst not affecting VET, take optimal benefit from the inodilatory enhancement of pump performance, 3) that an additional 131-adrenergic stimulation is proportionally less efficient, as VET is dramatically shortened, thus blunting the gain in SV so that the rise in CO relies substantially on the amplified increase of HR and 4), VET is more sensitive than QS2c in expressing additional 131-adrenoceptor agonism and 5) prime systolic time intervals provide a less speculative and physiologically more meaningful represenation of cardiac pump dynamics than HR-corrected ones.
Zentrum flit Kardiovaskul~re Pharmakologie, Mathildenstral3e 8, 55116 Mainz, BRD
A20
Regression between blunting of ergometric rise of heart rate and l~l-adrenoceptor occupancies in healthy man
The HR-responses to supine bicycle ergometry (4 min at appr. 200 Watt) were investigated at several time points after the administration of propranolol (PRO: 40, 80, 160 mg), carvedilol (CAR: 12.5, 25, 50, 100 mg), talinolol (TAL: 25, 50, 100, 400 mg), metoprolol (MET: 600 mg) and celiproIol (CEL: 1200 mg) to healthy man. The effects of the agents (= difference of the ergometric response for active drug and placebo) were analysed for both the end values (END) and the increments (INC) from resting values immediately before ergometry up to END. The effects were correlated with the %-~l-adrenoceptor occupancies estimated using a standard Emax-model (sigmoidicity=l) from the concentrations of active substrate in plasma determined by I~l-adrenoceptor specific radioreceptor assay. The respective intercepts (I), slopes (S) and correlation coefficients (r) are detailed here below : Inhibition of leukotrienes is a promising approach to the treatmer~t of several diseases because excess formation of these lipid mediators has been shown to play an important role in a wide range of pathophysiological conditions. Since until recently we were not able to obtain specific drugs suppressing leukotriene biosynthesis or action for clinical practice, we started investigating the effects of putative natural modulators of leukotriene biosynthesis such as fish oil. 10 healthy male volunteers were supplemented for 7 days with fish oil providing 40 mg eicosapentaenoic and docosahexaenoic acid per kg body weight and day. The urinary concentration of leukotriene E4 plus N-acetyl leukotriene E4 served as a measure for the endogenous leukotriene production, Treatment resulted in a significant increase in the eicosapentaenoate concentration in red blood cell membranes. Fish oil reduced the endogenous leukotriene generation in 8 of the 10 volunteers. The effect was associated with a decrease in urinary prostaglandin metabolites, determined as tetranorprostanedioic acid. In contrast to what was expected from published in vitro and ex vivo experiments, no endogenously generated cysteinyl leukotrienes of the 5 series could be identified. The inhibitory effect of fish oil on the endogenous leukotriene generation was not synergistic to the effect of vitamin E, which also exhibited some suppressive activity. Early clinical data on the effects of fish oil on teukotriene production in patients with allergy or rheumatoid arthritis are not yet conclusive. We conclude that fish oil exhibits some inhibitory activity on leukotriene production in vivo. The effectivity of fish oil may be attenuated by concomitant modulation of other mediator systems e.g. up-regulation of tumor necrosis factor production. • The number and affinity of platelet thromboxane (TXA2) and prostacyclin (PGI2)-receptors are regulated by several factors. We studied the influence of oral intake of acetylsalieylic acid (ASA) on ex-vivo binding studies with human platelet membranes on the binding of the specific thromboxane A 2 antagonist 3H-SQ-29548 and the PGI 2 agunist 3H-l]oprost. The number of receptors (Bmm) and the binding affinity (Kd) were calculated using Scatchard's plot analysis. In healthy male volunteers 11o significant difference was seen following intake of 500 mg/d of ASA for 14 days (mean -+ SEM): The potency of Meloxicam (Mel), a new anti-inflammatory drug (NSAID), in the rat is higher than that of well-known NSAIDs, In adjuvant arthrtitis rats, Mel is a potent inhibitor of the local and the systemic signs of the disease. Mel is also a potent inhibitor of PG-biosynthesis by leukocytes found in pleuritic exudate in rats. Conversely, the effect of Mel on PG-biosynthesis in isotated enzyme preparations from bull seminal vesicle in vitro, the effect on intragastric and intrarenal PG-biosynthesis and the influence on the TXB2-1evel in rat serum is weak. In spite of the high antiinflammatory potency in the rat, Mel shows a low gastrointestinal toxicity and nephrotoxicity in rats. -Cyclooxygenase-2 (COX-2) has been recently identified as a isoenzyme of cyclooxygenase. NSAIDs are anti-inflammatory through inhibition of PG-biosynthesis by inducible COX-2 and are ulcerogenic and nephrotoxic through inhibition of the constitutive COX-1. We have investigated the effects of Mel and other NSAIDs on COX-1 of non stimulated and on COX-2 of LPS-stimulated guine pig peritoneal macrophages. Cells were cultured with and without LPS for 6 hrs together with the NSAID. Arachidonic acid was then added for further 20 mins, the medium removed and PGE 2 measured by RIA.
IC~0 -7 to -1 -4 to 3 -8 to 0 -3 to 5 0.5 to 5.9 -3.4 to 1,9 4.9 to 11.8 * -3.9 to 3,1 -8.2 to -1.2 * -5.3tol,6 -5.1 to 2,0 -4.8 to 2.3 -2.9 to 6.6 -3.9 to 5.6 -0.25 to 0. Platelet aggregation is mediated by the binding of an adhesive protein, fibrinogen, to a surface receptor, the platelet glycoprotein lib/Ilia. GPIIb/llla is one of a family of adhesion receptors, integrins, which consist of a Ca++-dependent complex of two distinct protein subunits. Under resting conditions, GPIIb/llla has a low affinity for fibrinogen in solution. However, activation of platelets by most agonists, including thrombin, ADP and thromboxane results in a conformational change in the receptor and the expression of a high affinity site for fibrinogen. Binding of fibrinogen to platelets is a common end-point for all agonists and therefore is a potential target for the development of antiplatelet drugs. These have included chimeric, partially humanised antibodies (7E3), peptides and peptidomimetics that bind to the receptor and prevent fibrinogen binding. The peptides often include the sequence RGD, a sequence that is present in fibrinogen and is one of the ligand's binding sites. When administered in vivo, antagonists of GPIIb/llla markedly suppress platelet aggregation in response to all known agonists, without altering platelet shape change, a marker of platelet activation. They also prolong the bleeding time in a dose and perhaps drug dependent manner, often to more than 30 rain. In experimental models of arterial thrombosis, GPllb/llla antagonists have proved highly effective and are more potent than aspirin. Studies in man have focused on coronary angioplasty, unstable angina and coronary thrombolysis and have given promising results. 7E3 given as a bolus and infusion combined with aspirin and heparin reduced the need for urgent revascularisation in patients undergoing high-risk angioplasty, although bleeding was more common. Some compounds have shown oral bioavailability raising the possibility that these agents could be administered chronically. Antagonists of the platelet GPIIb/llla provide a novel and potent approach to antithrombotic therapy. Drug databases on computers are commonly textfiles or consist of tables of generic-names or prices for example. Until now pharmacokinetic data are not easily available for regular use, because searching parameters in a textfile is time consuming and personal intensive. On the other hand these pharmacokinetic data are the fundamental background of every dosage regimen and individual dosage adjustment. For many drugs elimination is dependent on the patients renal function. Renal failure leads to accumulation, possibly up to toxic plasma concentrations. Therefore, the decision was to build up a pharmacokinetic database. The aim is to achieve simplicity and effectiveness by using the basic rules. Only three parameters are needed to describe the pharmacokinetics: clearance (CI), volume of distribution (Vd) and half-life (T~). Moreover, with two parameters the third can be calculated ancl'controlled by the equation: Cl = Vd * 0,693 / T½ According to the Dettli-Equation and the Bayes' theorem estimation of individual pharmacokinetic parameters will be done by a computer program.
The advantage is that the impact of therapeutic drug monitoring can be increased. Using the population data and the Bayesian approach, only one measurement of serum drug concentrations might be enough to achieve an individual dosage regimens (El Desoky et al., Ther Drug Monitor 1993, 15: 281) Higher therapeutic security for the patient can be achieved. There is also a major pharmacoeconomic aspect: adapting drug dosage reduces costs (Susanka et al., Am J Hosp Pharm 1993, 50:909) The basic database for future pharmacokinetic clinical desicions is going to be built up. The pharmacokinetic interactions with grape#uit juice reported for many drugs are attributed to the inhibition of cytochrome P450 enzymes by nanngenin, which is the aglycene of the bitter juice component nadngin. However, only circumstantial evidence exist that naringenin is indeed formed when grapefruit juice is ingested, and the lack of drug interaction when naringin solution is given instead of the juice is still unexplained. We investigated the pharmacokinetics of naringin, naringenin and its conjugated metabolites following ingestion of 20 ml grapefruit juice per kg body weight, containing 621 IJM naringin, in 3 male and 3 female healthy adults. Urine was collected 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-16 and 16-24 hours alter juice intake. Naringin and naringenin concentrations were measured by reversed phase HPLC following extraction using ethyl acetate, with a limit of quantitation of 300 nM. Conjugated metabolites in urine were transformed by incubation with glucuronidase (28000 U/ml) / sulfatase (733 U/ml) from abalone entrails for 4 h at pH 3.8 and determined as parent compounds. Additionally, naringin and naringenin concentrations were measured in plasma samples from grapefl'uit juice interaction studies conducted previously. Neither naringin nor its conjugated products were detected in any of the samples. Naringenin was not found in plasma. Small amounts of nanngenin appeared in urine alter a median lag time of 2 hours and reached up to 0.365 % of the dose (measured as nanngin). After treatment with glucuronidase / sulfatase, up to 57 % of the dose was recovered in urine: Grapefruit juice was reported to inhibit the metabolism of a variety of drugs, including dihydropyridines, verapamil, terfenadine, cyclosporine, and caffeine. These drugs are metabolized mainly by the cytochrome P450 isoforms CYP1A2 (caffeine and, in part, verapamil) and CYP3A (others).
Theophylline has a therapeutic range of 5-20 mg/I and is also in part metabolized by CYP1A2. Therefore, we conducted a randomized changeover interaction study on the effects of concomitant intake of grapefruit juice on the pharmacokinetics of theophylline. 12 healthy young male nonsmokers were included. Theophylline was given as a single dose of 200 mg in solution (Euphyllin e 200), diluted by either 200 ml of water or 200 ml of grapefruit juice (D0hler GmbHi Darmstadt, 751 mg/I nadngin). Subsequently, additional fractionated 0.8 I of either juice or water were administered until 16 hours postdose. Theophylline concentrations in plasma withdrawn up to 24 hours postdose were measured by HPLC, and pharmacokinetics were estimated using compartment model independent methods. The study was handeled as an equivalence problem, and ANOVA based 90 % confidence intervals were calculated for the test (=grapefruit period) to reference (= water period) ratios (Trnax: differences). Lack of interaction was assumed if the 90 % CI were within the 0.80 to 1.25 equivalence range: 
The physical stability of erythromycin stearate film tablets was studied according to a 23 factorial design with experimental variables temperature, relative humidity, and storage time.
After one half year of storage at 40oc and 20% relative humidity, the fraction of dose released within 30 min in a USP XXl paddle apparatus under standard conditions decreased from 93% for the reference stored at ambient temperature in intact blister packages to 13% for the stress-tested specimens. Chemical degradation of the active ingredient did not become apparent before 12 months of storage. Under all other storage conditions, no effects of physical aging upon drug release were found. The bioequivalence of reference and stress-tested samples was studied in six healthy volunteers. The extent of relative bioavailability of the test product was markedly reduced (mean: 8.5%, range: 6-12 %), mean absorption times of the test product were significantly prolonged.
The results indicate that the product tested can undergo physical alterations upon storage under unfavourable conditions, and lose its therapeutic efficacy. It can be expected that this phenomenon is reduced by suitable packaging, but the magnitude of deterioration may cause concern. On the other hand, incomplete drug release is in this case easily detected by dissolution testing. Whether similar correlations exist for other erythromycin formulations remains to be demonstrated. The efficacy of a drug therapy is considerably influenced by patient compliance. Within clinical trials the effects of poor compliance on the interpretation of study results frequently leads to underestimating the efficacy of the treatment. In the evaluation of the "Lipid Research Clinics Primary Coronary Prevention Trial" and the "Helsinki Heart Study" special attention was focused on compliance with medication. The strong influence of compliance on clinical outcome and the dilutional effect of poor compliance on the efficacy of the respective drugs occured in both these trials. There are indirect (e.g. pill-count, patient interview) and direct methods (e.g. measurement of drugs, metabolites or chemical markers in body fluids) used to assess compliance with drug therapy. The indirect methods mentioned are commonly considered as unreliable. The direct methods can prove dose ingestion a short time before the sample is taken, however, they cannot show the time history of the drug use. An advanced method of measuring compliance is to use electronic devices. The integration of time/date-recording microcirculty into pharmaceutical packaging, so as to compile a time history of package use, provides real-time data as indicative of the time when dosing occurred. This method supports a precise, quantitative definition of "patient compliance" as: the extent to which the actual time history of dosing corresponds to the prescribed drug regimen. By taking real-time compliance data into account the results from clinical trials show not only clearer evaluations of drug efficacy and dese-reponse-relationship but also a better understanding of dose dependant adverse drug reactions. ) with left ventricular heart failure (group 3) with a PAPm of 36.5 ± 11.5 m3~HG. PAPM, right ventricular pressure (RVP), cardiac index (CI), heart rate (HR) and blood pressure (BP) were measered before and i0, 20, 30, 40, 50 and 60 min. after a bolus of 8 mg M iv. PAPm decrerased in group 2 18 % and group 3 32 %, whereas in group 1 only 3 %. CI increased in group 3 (+24 %), decreased in group 2 (-14 %) and was not changed in group i. In all patients we observed a decrease of BP and RVP. Thus we conclude that there is a benefit on the pulmonary hypertension due to left ventricular heart failure and due mitral valve stenosis caused by the reduction of preload, but we could not observe a NO-related effect on the pulmonary vascular system in pat. with precapillary pulmonary hypertension. Control of cell proliferation is a basic homeostatic function in multicellular organisms. We studied the effects of some prostaglandins and leukotrienes and of their pharmacological inhibitors on cell proliferation in murine mast cells and mast cell lines, in a human promyelocytic cell line (HL-60 cells) and in Burkitt's lymphoma cell lines. In addition, prostaglandin and leukotriene production was investigated in mast cells, representing putative endogenous sources of these lipid mediators. Murine mast cells were derived from bone marrow of Balb/c mice. Proliferation of cells was estimated using a colorimetric assay (MTT-test). Production of Prostaglandin D2 (PGD2), PGJ2, delta-12-PGJ2, Leukotriene C4 (LTC4) and LTB4 by mast cells was determined by combined use of high performanceliquid chromatography and radioimmunoassay. PGD2 and its metabolites PGJ2 and delta-12-PGJ2 exhibited significant antiproliferative effects in the micromolar range in mast cells, mast cell lines, HL-60 and Burkitt's lymphoma cell lines whereas inhibition of cyclooxygenase by indomethacin was without major effects. LTC4 and LTB4 had a small stimulatory effect on cell proliferation in HL-60 cells. Degradation and possibly induction of cell differentiation may have attenuated the actions of leukotrienes. The leukotriene biosynthesis inhibitors AA-861 and MK-886 reduced proliferation of HL-60 and lymphoma cells significantly but had no major effects on mast cell growth. On the other hand, mast cells stimulated with calcium ionophore produced PGD2 and its metabolites, as well as LTB4 and LTC4 in significant amounts. From our data we conclude that prostaglandins and leukotrienes may play an important role in the control of cell proliferation. We compared the pattern of drug expenditures of several hospitals in 1993 (size: 1000 to 1400 beds). A, B are university hospitals in the ,,old"and C,D,E are university hospitals in the ,,new" German countries, F is a community based institution in an ,,old" German country. Main data source were lists comprising all drags according to their expenditures in a rank order up to 100%. Items were classified into I) pharmaceutical products including immunoglobulines, II) blood and -derived products (cell concentrates, human albumin, clotting factors) and III) contrast media (x-ray). With regard to group I) the highest expenditures nccured in hospitals A and B whereas drug costs in C -E were 1/3 less and came to only 20% in hospital F. The main groups of drugs which together account for > 50% of these expenditures are shown in the table. products were about 20% up to 40% of group I and highest in hospitals A, B and E, but about 1/3 lower in hospitals C and D. These results suggest meaningful differences in the drug utilization between the old and new countries as well as betv,,een university institutions and community based hospitals. However, although all hospitals provide oncology and traumatology services and all university hospitals offer NTX, differences in other subspecialities e.g bone marrow and liver transplantation and treatment of patients with haemophilia must be considered, too. 
A38 ORGANIC NITRATE METABOLISM AND NITRIC OXIDE RELEASE IN VASCU-LAR TISSUE AND IN PLATELETS
M. HGnicka, R. Spahr, M. Feelisch, and R. Gerzer Organic nitrates like glyceryl trinitrate (GTN) act as prodrugs and release nitric oxide (NO), which corresponds to the endogenously produced endothelium-derived relaxing factor. In the vascular tissue, NO induces relaxation of smooth muscle cells, whereas in platelets it shows an antiaggregatory effect. Both activities are mainly mediated via stimulation of soluble guanylyl cyclase (sGC) by NO. In contrast to compounds which release NO spontaneously, a membrane-associated biotransformation step is thought to be required for NO release from organic nitrates. Glutathione-S-transferasea and cytochrome P-450 enzymes have been shown to metabolize organic nitrates in the liver, but little is known as to whether these enzymes are involved in the metabolic conversion of organic nitrates in the vasculature. Furthermore, it is still unclear whether or not platelets are capable of metabolizing organic nitrates to NO. We isolated the microsomal fraction of bovine aorta in order to characterize the activities towards organic nitrates using the guanylyl cyclase reaction as an indirect and the oxyhemoglobin-technique as a direct measure for NO liberation. GTN was metabolized to NO by the microsomal fraction under aerobic conditions already in the absence of added cofactors. This activity was not influenced by the cytochrome P-450 inhibitors cimetidine and metyrapone. In contrast, the glutathione S-transferase substrate 1-chloro-2,4-dinitrobenzene and the glutathione S-transferase inhibitors sulfobromophthalein and ethacrynic acid did not affect NO release, but potently inhibited sGC activity. Blocking of microsomal thiol-groups resulted in a decreased NO release from GTN. Homogenates of human plateles isolated by thrombapheresis and stabilized by addition of 5 mM N-acetylcysteine did not show NO-release from GTN as determined by the stimulation of the platelet sGC even after addition of the possible cosubstrates glutathione and NADPH. These data demonstrate (1) that bovine aortic microsomes exhibit an organic nitrate metabolizing and NO-releasing activity whose properties are clearly different from classical cytochrome P-450 enzymes and from glutathione S-transferases, and (2) Acesal ® and Micdstin ® were bioequivalent in rate and extent of absorption with the reference formulations. The fast liberating Acesal ® Extra was bioequivalent with respect to extent only. ASA from Miniasal ® was absorbed more slowly than from an ASA solution (Cm= (68%-range): 264-536 ng/ml and 387-726 ng/ml; t~ (min-max): 0.33-2.0 h and 0.17-0.5 h). ASA from Micdstin ® and the corresponding reference was absorbed more slowly than from Acesal ® and Acesal ® Extra. This was accompanied by decreased AUCAsA (increase of first pass metabolism) and increased apparent trrz (absorption being rate limiting). All ratios of AUCsA/AUCAsA after administration of 500 mg ASA were markedly higher than after 30 mg ASA. Thus, the formation of salicyludc acid from SA might be capacity limited at doses of 500 mg ASA. In the study >>Physicians' Assessment of Internal Practice-Conditions and Regional Health-Services-Conditions in Accordance with Ambulatory Patient-Management<< a sampie of 130 primary care physicians -comprising GPs and internists -provide data for continuons analyses of arnbulatory health care quality and structure. Focussing on the physicians' drug prescription, the impacts of 1993 reform law (Gesundheitsstralcturgesctz, GSG) upon primary care providers and their therapeutic decisions were examined in 1993. Four different surveys were carded out during the year, dealing with frequent patients' reasons for encounter in GPs' offices. After a pretest was carried out, physicians reported on 3728 patient-physician-encounters, basing on mailed questionnaires. For every therapeutic change patients received, the reasons for the change were recorded (e.g, reform law, medical indication) and above the physicians' expectations towards three criteria to measure the quality: 1) physicians' assessment of the patients' satisfaction, 2) adverse drug effects, 3) therapeutic benefit. According to therapeutic changes due to 1993 reform law (drag budgets, blacklist) it can be stated: 1) Therapeutic changes due to reform law were carried out with relevant frequency.
2) The reform law was of different concern regarding the different reasons for encounter we investigate& 3) The impacts' strangth of the legal control mechanisms differed among several groups of physicians: Those who already have been liable to recourse before 1993 more often carried out therapeutic changes according to fixed drug budget. Different multivariate logistic regression-models yield an estimation of the odds-ratio of about 3. 4) Therapeutic changes in accordance with the 1993 reform law having been carried out at the beginning of the year more often suffered from negative expectations towards the therapeutic quality then changes during the actual encounter, e.g. >>joint pains<c 26% decrease of the therapeutic benefit in contrast to 7%. During the year a decrease of negative expectations is noticable. 5) Patients overestimating the severity of their own health problem in comparison to the physician more often suffered from negative expectations towards the therapeutic change than other patients, e.g. concerning the therapeutic benefit (29% in contrast to 3%). Generally speaking, firstly the reform law led to insecurities -particularly in the introduction phase -among susceptible subgroups of physicians and patients, regarding the four investigated reasons for encounter. Secondly, there is evidence of a loss of quality in ambulatory health care -predominandy in terms of subjective criteria. These impacts considerably subsided within the field phase duration from May to November, 1993. The presented analyses give evidence of the practicability of studies assessing effects of legally-initiated mechanisms to control health costs upon primary health care quality. Postansehrifi: ISEG, Bissendorfer Sm 9, D-30625 Hannover The cellular and biochemical mechanisms that lead to the longerm complicatiorts of diabetes mellitus are poorly understood. Glycation is a multireaetion beginning with a condensation reaction between reducing sugars and reactive amino groups of proteins. The accumulation of the glycated products of various proteins may contribute to the development of the complications of diabetes and aging. In order to find suitable non-toxic glycation inhibitors we used sulfur deriva-tives (penicillamine, eaptopril and alpha-lipoic acid) and amino derivatives (aminoguani-dine and aminoguanidine propionic acid) and postulated the mechanisms involved.The inhibitou effect of the drags on the early (Amadori product) and advanced glycation products (AGE). determined by affinity chromatography, deglycation method. I-IPLC and fluorescence spectroscopy, differs markedly depending on the drag used and is greatest (up to 80 %) with aminoguauidine and penicillamine (20 mM) and smallest with alpha-lipoic acid. Aminoguanidine propionic acid had no inhibitory effect on the glycation process. The ability of penicillamine to inhibit both the formation of Amadori products and AGE was demonstrated by isolation of the adducts of penicillamine with ribose, glucose, glucosa-mine and p-tolylglucosamine, a standard for glycated protein. Their structures were characterized using IR-and 1H-NMR and 13C-NMR spectroscopy. The oxidative deg-radation of glycated human serum albun{in in the presence of copper (II), forming the carbox3Jmethyllysine, was inltibited by the sulfur derivatives. The in vitro formation of pentosidine, a crossliuking product was influenced by all drugs used However captopril, alpha-lipoic acid and aminoguanidine propionic acid do not condense with sugar derivatives.The mechanism by which captopril and alpha-lipoic acid inhibit the formation of AGE may be involve radical formation, where a spontaneus thiol/disul-fide interchange between drug and protein takes place. Complications can appear at any time in diabetic patients.The cause of these complica-lions in some cases may be due glycation and/or oxidation. The clinical applications of substances which are able to prevent these events may have advantages. These results and the mechanism proposed show that the amino and sulfl~ydryl groups of drags reduce glycation and postglycation of proteins and thus have potential value in this regard. Non-enzymatic glycation starts by covalent binding of single sugars to o~ or E amino groups of proteins. In subsequent reactions a number of early glycation products like Schiff bases or Amadori products, and of advanced glycation endproducts (AGEs) is formed. Glycation is increased in a variety of proteins in diabetic patients [Schleicher E (1992) Diabetes und Stoffwechsel 1: 274] including human serum albumin (HSA), the red cell membrane, hemoglobin, collagen, laminin, immunoglobulin G, low-and high-density lipoproteins. The process is supposed to be a key mechanism in the pathogenesis of diabetic complications and in tisstie ageing [Vlassara Het al. (1994) Lab Invest 70: 138] . Inhibition of glycation may therefore be important for the prevention of late diabetic complications. We investigated the in vitro glycation of human serum albumin (HSA) and its inhibition by aminoguanidine, penicillamine, captopril and c~-lipoic acid (20 raM). HSA (40 g/l) was glycated by incubation with 20 mM glucose in 0.1 M phosphate buffered saline, pH 7.4, at 37 °C for 28 days under sterile conditions in the presence of 0.1% natrium azide. The glycation rate was determined by two different methods: Deglyeation -measures Amadori products based on the colorimetry of 2-ketoglucose which is released from the glycated protein (ketoamine) on heating with hydrazine [Kobayashi K et a1.(1993) The effect of aniseylated #asminogen streptokinase activator complex (APSAC) on left ventricuiar (LL r) function ;,.,as investigated in ! 5 patien~ with acute myocardial infarction (AM!). A dose of 3Q units APSAC was given intraveneusiy to patien~ with AMI within 4 hours after onset of pain, Patients underwent cardiac angiegraphy at 90 minutes and at day 28. Wail motion ,.~s measured by the global ejection fraction and by the centefline method in :'=he infarct and neninfar~ regions and expressed in units of sf~ndard deviations beiew normai, as defined in 50 normai patient. Group A with successfui ',th, rombo!ysis (TiMi 2 and 3) was compared with group B without successfui thrombolysis (TiMi 0 and !). At 90 minutes there vras no significant difference in giebal ejection fraction between both groups, By using the regiona! wa[i motion by the centerline method group A showed a significant improvement of LV function (p ~ 0.05). The benefit of successEli thrombeiysis was more marked in the peripheral infarct region than in the centrai infarct region. Thus early repeffusion is an important factor in maintaining good LV function after AMi. The re=gionai wai! motion in the infarct region seems to be more sensmve man me g!oba! eiection fraction to show ear!y differences in LV function after AMi. Switzerland, but their effect on the expression and function of the multiple drug resistance gene product has not been studied in detail. We have therefore examined the effect of GM-CSF and G-CSF on the uptake and toxicty of vincristine with and without the chemosensitizers R-verapamil and norverapamil in the Pglycoprotein-containing vincristine-resistant cell-line, HL-60/vi,o. Following a 48h pre-incubation with 10 ng/ml G-CSF or GM-CSF, cells were washed and reincubated in RPMI medium with3H -vincristine and the modulators for 4 hours. The uptake of3H -vincristine was increased up to 2-fold and this effect was equally marked when the vincristine-uptake was stimulated with the chemosensitizers in the range of 2.5 pg/ml to 10pg/ml. Although cytokine-pretreatment increased the accumulation of vincristine, we could not show an increase in vincristine toxicity over 72h with the same concentrations of vincristine and chemosensitizers. It is concluded that the effects of cytokines on vincristine accumulation are compensated by a positive effect on cell-survival or cell-growth. From the economic point of view people often tend only to regard the price of a product. Savings for the health care system as a whole which could be gained by use of these drugs and which could more than compensate the high costs of medication are not considered. The cost-benefit-analysis enables a comprehensive analysis of the economic effectiveness of a pharmaceutical. The relevant cost factors such as the costs for in-and out-patient treatment depending on the therapeutic success and the inability to work are compared to the costs of medications. Using the example of stroke prevention, it was possible to show that prophylaxis with an expensive but effective pharmaceutical is economically better than standard medication. According to the TASS study Ticlopidine can prevent at least 3 more strokes per i00 treated patients than ASS. On the basis of this study cost savings of up to DM 92,000 per i00 treated patients can be reached including higher costs of Ticlopidine.
Projected onto i00,000 patients up to DM 92,000 per year can be saved for the German health care system by the use of Ticlopidine in secondary prophylaxis after TIA. The naphthodianthrones Hypericin (H) and Pseudohypericin (PH) were proved to be elfectire in mild depressive disorders. Recently they were discovered to exhibit high in vitro activity against enveloped viruses fostering clinical trials in infections with HIV or herpes viruses, For studying the pharmacokinetics of H and PH a solidified extract from St. John's Wort (Hypericum pefforatum L) was orally administered to 12 healthy male volunteers in three single doses of 250, 750, and 1500 ~g of H and 526, 1578, and 3156 p.g of PH, followed by a 14-days course of multiple dosing of 250 p.g H and 526 pg of PH tds. Plasma concentrations were determined by HPLC, the quantification limit was 0.2 #g/I (Staffeldl et al., Nervenheilkunde 12(1993): 331). Single,dose kinetics, H showed a median lagtime of 1.9 (range: 1,4-2.3) h, which was significantly longer compared to 0,38 (range: 0.5-1,0) h of PH. H was eliminated with a median half-life of 36 (range: 12 -56) h, and in case of PH the hail-life ranged between 5.0 and 36 (median: 16,5) h. Median Crux levels were 1.3, 7.2, 16.6 ~g/I for H and 3.4, 12.1, 29.7 pg/I for PH for the three single-dose levels given above, respectively. Lowest dose Crre, x and AUC of H was lower then expected from medium and highesl dose, which was statistically significantly for Crnax (p=0.049, Anova; p=0.0156, 8onferroni/Dunn), indicating nonproportionality of pharmacokinetic response may exist in the lower dosing range. Mul!iple-dose kinetics. During long-term dosing steady-state trough levels (Ctreugh) of 7.9 (range: 3.4 -13.6) ~g/I for H and 4.9 (range: 12 -tO.9) ~g/I for PH were reached after 4 days for both. Cmax after 14 days of treatment were 8.8 (range: 5.8 -22.1) ~g/I for H and 8.5 (range: 4.3 -20.7) for PH, this is about 2/3 of the Crnax reached after the corresponding single-dose of 250 ~g H and 526 ~g PH. The AUC for one dosing interval of 187 (range: 98.5 -337) ,u.g.h/I for H and 121 (range: 41,7-244) ~g.h/I for PH is statistically not significant different to the corresponding singledose AUC (interpolated to the same dosing interval) of 207 (range: 135 -448) and 137 (range: 84.9 -466) p.g.h/I for H and PH, respectively. Therefore acceleration of firstpass-metabolism due to enzyme induction is unlikely during steady-state treatmenl in the dosing-range investigated. Plant extracted versus chemically synthesized H. To investigate the influence of galenics or other substances in the plant extract one single-dose of 750 ~g of chemically synthesized H (in a 10% alcoholic solution) was given to one of the volunteers. Crnax and AUC were 2.6 pg/I and 73.6 p.g .h/I, respectively, compared to 7.7 i~g/I and 145.6 #g.h/I after the equivalent dose of solidified extract, No difference was noticed in the lagt~me (H in plantal extract: 1.35 h versus chemically synthesized H: 1.5 h). Different sites of intestinal H and PH absorption may give an explanation, but this remains to be experimentally proven. C. Kori-Lindner, R. Eberhardt
The Healthcare Restructure Act (1993) changed the evaluation of drugs from efficacy to cost effectiveness: therapeutic necessity, utility, purpose; medical progress and economic utility have to be considered. Criterias and suroundings of pharmacooeconomic evaluations and studies according to the Bealthcare Restructure act are demonstrated by an example: "Costs of NSAID-induced gastro-duodenal ulcers and prevention with miso~rostol". Methods: Cost-utility, Cost-benefit, legal requirements, decision-model and decision -tree, basic calculation and the transfer to the socialsystem of the FRG. Premissions: rate of ulcers without prevention 21,7%, with prevention 5,6%; rate of compliance 70%, rate of hospitalisation 20% and duration of hospitalisation 16,6 days. (Arzneimittelindex 1992) demonstrate that the group of antirheumatics/analgetics held the first rank due to the number of prescriptions. With regard to the costs thts drug class were amongst the top three. Apart from anUrheumatics and analgetics different other drug classes are used for the treatment of rheumatic disorders for example corticoids. To estimate the total expenditure for drug utilization in out-patients suffer from musculoskeletal disorders data of the statutory health insurance Dortmund (AOK Dortmund) were investigated. A 5% random sample of insurees (n=6478) was analysed for diagnoses and drug therapy. The data were collected in a individual-related way for an observation period of one year (1988) . The results demonstrate the high frequency of rheumatic disorders among out-patients: the 12-month prevalence of musculoskeletal disorders was about 40% in the studied population of whom one half suffered from back pain. Approximately 80% of the patients were prescribed any drugs for treatment of rheumatic disorders. As might be expected nonsteroidal antiinflammatory drugs were used most frequently. The extensive use of topical products was a considerable factor of costs. More than one half of the patients received drugs for topical application. Further details will be presented. Diachronous data of statutory health insurences that have been gathered in a person-related way permit the estimation of drug expenditure in outpatients with regard to the several musculoskeletal disorders. Misleading results of endocrine tests in patients suffering from liver diseases promted us to investigate the influence of liver function on the pharmacokinetics of dexamethasone (DEX). It was the aim of this study to find out whether routine parameters of liver function may be usefull in roughly predicting the clearance of dexamethasone. Methods : In 50 patients liver function was rated on the basis of their plasma cholinesterase activity (CHE) and prothrombin time (PT). Blood samples were withdrawn 7, 15, 30, 60, 120, 240, 360, 480 and 960 min following an iv bolus injection of 2 mg of dexamethasone-21-dihydrogenphosphate corresponding to 1,66 mg of DEX for the determination of DEX pharmacokinetics by RIA. Results : Computer assisted best fit analysis (2 compartment model) of the plasma DEX decay did not show any influence of liver function on the distribution half-life (t½-a) and on the initial volume of distribution of DEX, but a 56 % increase in the terminal phase, "metabolic" half-life (t½-B) with decreasing liver function. While the t½-B increased from 167 ±12 min in patients with a CHE activity >5.0 kU/l to 253 ± 14 min in those with a CHE S 1.0 kU/l, the metabolic clearance rate (MCR) decreased from 226 ±29 ml/min to iii ±180 ml/min. In patients on phenytoin the t½-B was reduced to <i00 min. CHE activity (r=-0.454) and PT (r=-0.447) were significantly (p<0.001) correlated with the t½-B of DEX. We conclude that the dosage of dexamethasone given for diagnostic or therapeutic purpose needs to be adjusted in patients on phenytoin therapy and in patients with liver disease causing a CHE S 2 kU/l. Etofenamate is one of the most frequently applied topical NSAIDs in Germany. It can be regarded as a lipophilic prodrug of flufenamic acid, which is liberated after transdermal absorption and cleavage of the ester. We compared several topical NSAIDs in patients suffering from osteoarthrosis or rheumatoid arthritis with concomitant knee joint effusions. The products contained between 5 and 10% of etofenamate and were administered according to the recommended dosage schedule. Following multiple applications of defined doses we obtained synovial fluid and plasma specimen in order to measure the concentrations and to compare the bioavailabilily of several products. The analysis of synovial fluid and plasma samples was achieved by HPLC. Following the addition of other N-phenylanthranilic acid derivatives as internal standards the samples were extracted twice with a 5-fold volume of acetonitrile/methanol (1:1). The diluted extracts were concentrated with the use of preconditioned ODS-columns and subsequently eluted with methanol. The separation of the products was perlormed on a reversed phase column with an elution medium of methanol/water/acetic acid (72:27.9:0.1). The highest synovial fluid and plasma concentrations were measured after 3 hours following the final administration of etofenamate. The concentrations reached average maximum values of 60.5 ng/ml of flufenanamic acid in plasma and 45.1 ng/ml in synovial fluid. The bioavailability could be estimated from the area under the concentration time interval between 0.5 and 3 hours, during which samples were obtained. They served for the comparison of the topical products. From in vitro data of cyclooxygenase or lipoxygenase inhibition with N-phenylanthranilic acid derivatives it can be concluded, that the synovial fluid levels of etofenamate and its metabolites are unsufficient to produce effects relying on this mechanism. It can not be excluded, however, that other effects contribute to the clinical improvements observed by other investigators. Introduction: Meloxicam (MEL) is a new non-steroidal antiinflammatory drug (NSAID) belonging to the enolic acid class. In animal studies it has been shown to have excellent anti-arthritic efficacy and an improved tolerability profile over other NSAIDs. Early preclinical studies have shown that MEL preferentially inhibits cyclooxygenase-2 (COX-2). The aims of this three-week, parallel, multicentre trial were to assess the efficacy anct safety of two different doses of MEL in comparison to placebo (PLA) in patients with active RA. The specific question was, whether COX-2 inhibition relates to therapeutic efficacy and safety in the clinical'setting. Methods: 468 patients (337 F, 131 M, mean age 55 years) were randomised (MEL 7.5 mg=159, MEL 15 mg =162, PLA=147) and analysed by an intention-to-treat analysis. All trial drugs were given orally once daily. Results: 31 patients (21%) in the PLA group, 11 patients (7%) in the 7.5 mg MEL group and 16 patients (10%) in the 15 mg MEL group discontinued the trial prematurely due to lack of efficacy or adverse events. 15 mg MEL was significantly superior (p<0.05) to PLA in 3 of the 4 primary endpoints: disease activity assessed by the investigator and by the patient and reduction of the tender/painful joint count. The difference between 7.5 mg MEL and PLA reached statistical significance in 2 of the 4 primary endpoints: disease activity assessed by the patient and reduction of the tender/painful joint count. In none of the primary endpoints a statistically significant difference between 15 mg and 7.5 mg MEL occured. Global tolerance assessed by the patient and investigator at the last trial visit was similar in all three treatment groups. Adverse events were slightly more frequent with meloxicam than with placebo. In none of the patients gastric or duodenal ulcers, perforations or bleeds were observed. Conclusion: The efficacy of meloxicam 7.5 mg and 15 mg per day was significantly superior to placebo in the treatment of patients with RA. There were no relevant differences regarding safety parameters between the 2 meloxicam doses and placebo. The preferential COX-2 inhibition may be the reason for the favorable efficacy and safety profile of meloxicam. The major metabolites of morphine are morphine 3-0-B-D-glucuronide (M3G) and morphine 6-0-13-D-glucuronide (M6G). In humans plasma AUCs of M3G and M6G exceed those of morphine depending on form and route of application. M3G and M6G penetrate the blood-brain-barrier due to an unexpectedly high lipophilicity, M3G is an antagonist able to provoke with&awl symptoms even in opioid naive animals. M6G is an agonist markedly more potent than morphine.
Methods: Pig brains were homogenized and the homogenate centrifuged to give a microsomal preparation free of nuclei and coarse debris. Aliquots were incubated at 37°C in buffer (pH 7.4) containing 0.5 nM [3H]DAMGO.
Results: The IC50 for morphine, M3G and M6G were 3.7 nM, 24 nM and 1.2 pM, respectively. M6G and M3G, respectively, shifted the IC50 for morphine markedly to the right. Discussion: Our results on the single substances confirm data from the literature indicating that M3G and M6G inhibit binding to the ~t-OR less potent than morphine.
From the fact that M3G and M6G shift the IC50 for morphine to the right we infer binding of M3G and M6G to the morphine binding site at the ~t-OR. [ntensiv care units are the most expensive wards consuming 15-20% of the hospital budget, Drug use reviews on SICU's of the university hospitals Frankfurt (22 beds) and Jena (25 beds) were compared after recording the indication related administration of pharmaceuticals and blood products over a 4 months investigation period using notebook-PC's. All substances were included, wich produced 60% and 80% of total pharmacentical cost in the year before, respectively. In Frankfurt and Jena 207 and 465 patients were registered, causing total cost of DM 938.000,-and DM 1.145.000,-and causing cost per patient and day of average DM 796,-and DM 513,-, respectively. In Jena most expensive diagnoses were severe trauma (38 8% of total cost; n=66), gastre-intestinal bleeding (14.9%; n=16) and malignant growth (14.3%; n=100). In Frankfiart nigh cost diagnoses were liver transplantation (27% of total cost; n=2l), severe trauma (10,5%; n=22) and coronary bypass craRing (9.3%" n=73). Although the patient populations were different, the percentage cost of the substance groups on total drug cost were the same in both SICU's: blced-products 57±1%, antibiotic and chemotherapeutics 19iO,5%, immuna-ghibulines 10,5:t2,5% Anyway, inside these groups drug usage patterns differed distinctly. For example, in Jena the nigh-cost antibiotics were tobramycin, cefuroxim, amoxicillin and AmBisome ® causing 16.2 %, 12.3 %, 8.1% and 8% of total antibiotic cost, respectively. Corresponding data for Franlffurt are AmBisome* 39.8%, Imipedem 14.3%, Cefotaxim 7,4% and Cefamandol 6.5%. Severe sepsis was the most abundant complication occuring in beth SICU's in 7 patients and producing cost of DM 208.695,-in Frankfurt and DM 173.676,-in Jena. In sepsis blood products were the most expensive substances with 52.9% (Frankfurt) and 38.9% (Jena) followed by antibiotics with 26.2% and 14.3% and immuneghibulines with 17.1% and 36.8%, respectively Conclusion: * Recording the indication related drug administration drug usage patterns may be identified and targets for economical intervention may be found.
• Blood and blood-products must be included because they produce about 50% of total cost.
• Complications, especially sepsis, produce nigh cost, which should be included in the discussion with the health assurances concerning the payment system using diagnosis related groups. In 1992 a Drug-Utilisafion-Review-Group (DURG) was founded by Clinical Pharmacologists. The task of this group is to identify drug usage patterns, to record indication related drug administration including cost and to analyse these data. As a result recommendations concerning rational and economical use of pharmaceuticals and blood-products were given (e.g. 5HT3-receptor-antagonists, human albumin, G-CSF). The cost-development (million DM) of all substances during the last 11 years is shown in the The most expensive substances are blood-products (27%), antimicrobial agents (27%) and immunoglobulines (21%).
In conclusion, at the Universitiy Hospital FrankfurVMain the activities of the Drug-Utilisation-Review-Group seem to be successful and are at least inpart responsible for the reduction of drug-cost of more than DM 10 Mio last year. The aim of this study was to determine the extent and the time course of fenoterol induced tachycardia and hypokalemia during and after a continuous intravenous infusion with three different rates within the therapeutic range for tocolysis. Furthermore we compared the point estimators and precision of parameters obtained with a standard two step approach and a population model. According to a randomized double blind multiple cross over design, 6 healthy females received an intravenous infusion of either placebo or fenoterol (0.5 IJg/min, 1 IJg/min, 2 lJg/min) over 3 hours. The plasma concentration of fenoterol, heart rate, blood pressure, plasma potassium and plasma glucose were monitored during and up to 2 hours after the infusion. The plasma concentrations of fenoterol and potassium and the heart rate were fitted to an integrated PKPD model. Both individual parameter estimates and population estimates were obtained with NONMEM. Both effects correlated best with the concentration in the central compartment. The relationship between heart rate and concentration was adequately described by an Emax model. Modelling of the dose dependent hypokalemic effect of fenoterol required an negative sigmoid Emax model with an additional term allowing for passive diffusion of potassium from the intra-to the extracellular compartment. During the observation period, the concentration response relationship remained stable for both effects. As to be expected, the estimates of the population parameters were much more stable than those of the individual patients. It is concluded that the population method might be superior to the STS approach even in a data rich situation. 18 volunteers received 3 different controlled release formulations (A, B, C, containing 60 mg IS-5-M2",1) in a randomised cross-over design. Plasma samples were taken from 0 to 48 hours after application. One week wash-out phase was kept between investigations. IS-5-MN were determined in plasma using a GC-method. In vitro dissolution of A, ]3, C was investigated by using the rotating bottle method according NF XIV.
Mean absorption time (MAT) was calculated as the difference of MRT and ke1-1, the mean dissolution time (MTdiss) was calculated as proposed by Brockmeier (1). Additionally half value duration (HVD) and plateau time OPT) are reported. 159±7 vs 162±5 mmHg) . In the postpacing ischemic period, LVEDP fell from a mean of 28.9 to 18.4 mmHg after enoximone (p<0.001), dp/dtmax increased from 1050 to 1369 mmHg/s (p<0.001) and regional EF from 47% to 58% (p<0.01) with global EF remaining unchanged (45% vs 47%). ST segment depression was reduced significantly from 2.3 to 1.5 mm (p<0.01). Enoximone induced an increase in myocardial perfusion by 129% (p<0.001) in the stenosis-depending myocardial areas with shortening of the wash-out half-time of the echo contrast medium from a mean of 14 to 5 s (p<0.001) . The isovolumetric relaxation (ECHO) was shortened by 13% (p<0.05), the E wave by 5%, and dp/dtmin was increased by 17% (p<0.01 
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CARNITINE DEPLETION IN CHILDREN SUBSTITUTED B-LACTAM ANTIBIOTICS I. M~lIer and M. Kurowski
TREATED WITH PIVALOYLPivaloyl-substituted 8-1actamantibiotics belong to a new group of prodrugs with an improved bioavailability following oral administration. After metabolic cleavage the pivalic acid and the free 13-1actam are eliminated separately. Pivalic acid is subjected to enzymatic coupling with endogenous camitine leading to carnitinepivaloylesler, which can be found in large amounts in the urine. Free camitine is reduced under the treatment which may lead to neurological side effects in patients with metabolic predisposition. We showed, that the pattern of other acylcarnitineesters excreted with the urine was not changed significantly after administration of a pivaloyl.substituted cephalosporine in healthy subjects. In order to compare the pattern of excreted carnitineesters we analyzed urine samples of pediatric patients treated with cefetamet-pivoxil. The analysis of carnitineesters in the urine was achieved by HPLC following precolumn derivatization. As an internal standrad we used undecanoyl-carnitine aster, which does not occur in human plasma or urine. After the extraction using ion exchange columns the samples were incubated with p-bromo-phenacyl reagent. The mixture of derivatives was separated on a reversed phase column applying a gradient of different buffers. With this method the whole spectrum of carnitineesters can be quantitatively analyzed. The percentage of the pivalic acid ester eliminated with the urine in pediatric patients did not differ from that observed in healthy subjects, therefore an increased risk in this patient group cannot be inferred. Institut for Klinische Pharmakologie, Universit~.tsklinikum Charit& HumboldtUniversit&t zu Berlin, Schumannstral~e 20, D-10098 Berlin;
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Pharmacokinetics and bioavailability of Bupranolol-l"rS and oral Bupranolol in patients with impaired liver function compared to healthy volunteers K.-H. Molz*, W. Cawello**, G. Haug-Pihale*", R. Bonn** W. Hammes**, A. Weil*** and G. Popescu*** Bupranolol is nearly completely absorbed after oral administration, but more than 90% of the parent compound are metabolized by first pass through the liver. It can be expected that transdermal application of the substance will bypass the high first pass metabolism resulting in higher plasma concentrations or lower therapeutic doses, respectively. A reduced capacity of metabolizing liver enzymes might mimic this effect. The study was performed to investigate if metabolisation by hepatic enzyme systems results in liver function dependent pharmacokinetics. Special interest was to be given to possible differences between oral and transdermal application. In an open sequential single dose-study including 10 patients with impaired liver function and 10 age/sex/weight-matched healthy volunteers a bupranolol transdermal therapeutic system (containing 30 mg/24h) and bupranolol tablets (100 mg) were administered to each participant separated by a washout period of a week. Phenotyping for mephenytoin and sparteine was done to exclude poor metabolizers. Blood samples for the quantification of bupranolol plasma concentrations were drawn before and 1, 2,3,6,9,12,16,23,24 (before patch removal), 25,27,30,36,48,60 and 72 hours after patch application as well as before tablet administration and 0.5,1, 1.5,2,3,4,6,8, 10,12,16, 24,30,36,48 and 60 hours post dose. Urine samples were collected in 5 ('ITS) and 6 (tablets) intervals after dosing. Blood pressure and heart rate were measured before and 1,3,6,12 and 24 hours after dosing, ECG's were recorded before and 3,6 and 24 hours after dosing. The pharmacokinetic results indicate only minor differences between patients and healthy controls after patch applications. For example the main parameter AUC(0-~) were 65.8±26.3 ng/ml.h (mean±sd) in healthy controls and 57.8±18.1 ng/ml.h in patients. Completely other situation was given in comparison of data from oral administration: AUC(0-=)decreased dramatically to 5.7±3.7ng/ml-h in healthy controls and increased to 473.3±611.6 ng/ml.h in patients. The purpose of the study was to investigate whether this phenomenon 1. implies general impairment of the nitric oxidemediated relaxation (or only specific interference with muscarinic receptors), and 2. can be also demonstrated for coronary arteries. Porcine coronary arteries were cut in rings and were set up in organ baths for isometric tension recordings. Rings were randomized and incubated with different glucose concentrations (5.5, 22,0, or 44.0 mM) for 6 hours according to Cohen and coworkers. Rings were preconstricted with prostaglandin F2 ~t (0.5 -3 ~M); the nitric oxidemediated relaxation was induced by either substance P (0.01 -10 nM), bradykinin (0.1 -100 nM), or calciumionophor A23187 (1 -1000 nM), the endothelium-independent relaxation by nitroglycerin (1 -3000 nM). In addition, the effects of glucose were studied on acetylcholine-(0.01-10 ~tM) and serotonin-(0.001 -10 ~M) induced vascular responses.
Results: Surprisingly, elevated glucose concentrations (22 and 44 mM) had neither an effect on the potency nor the efficacy of any of the agonists tested. It is concluded that this previously reported impairment of endothelium-mediated vasodilation of rabbit aorta by elevated glucose concentrations may not be important in other species or types of arteries.
Division of Cardiology, Hannover Medical School, 30625 Hannover, Germany Nitric oxide production may be induced by cytokine-mediated immune responses. We tested the hypothesis that graft rejection in cardiac transplanted patients is associated with an increased production of nitric oxide. The study group consisted of 83 patients in whom one or several myocardial biopsies (total 194 biopsies) were obtained to assess for graft rejection. At the day of biopsy, urine was collected for a time period of at least 4 hours (10% isopropanol was added for antimicrobial activity). Nitrate was measuerd in urine samples by gaschromatography. Nitrate excretion was expressed as the quotient of nitrate and creatinine content (gmol nitrate/mmol creatinine). Since nitric oxide is oxidized in biologic systems to nitrite and finally nitrate, it was assumed that nitrate excretion reflects total nitric oxide release. Graft rejection was classified according to the Hannover classification System (A0/I= no/minor rejection, A2-A4=moderate/severe rejection). Results: Nitrate excretion showed a large interindividual variation (9 to 502 I.tmol nitrate/mmol creatinine). /£1tough not significant, the nitrate excretion tended to increase with the degree of rejection (A0: 99+ 9; A 1: 128 + 12; A2:131 + 15; A3/4:128 + 15; mean + SE). In a subgroup of patients (n=32) The combination of thremboxane A~/prostaglandin endoperoxide (EPO) receptor antagonism with thromboxane synthetase inhibition (TRASI) is designed to both abolish the EPOs' prothrombotic role and direct EPOs from activated platelets to adjacent cells for the generation of antithrombotic prostaglandins. Thus, we have investigated the effect of the potent TRASI DT-TX 30 on thrombus formation in models of vascular injury (of the media versus selective deendothelialization) in man ex vivo. Healthy volunteers were treated with an oral dose of vehicle (placebo; n=10) or 50, 100, 200 , 400 mg; n=6 per dose). Blood was taken before and 1, 2, 4 and 24 h after the ingestion, anticoagulated and allowed to flow over a thrombogenic cell-free subendothelial matrix (CFM) or a layer of human venous smooth muscle cells (SMC) for 10 min. The "en face" area of platelets/thrombi deposited was determined by microscopic morphometry.
In the absence of cells of the vessel wall (CFM) the thrombus formation was inhibited by 32+15% (+SD) after 50mg, 43+_28% after 100mg, 31+1% after 200mg and 57+P9% after 400mg DT-TX 30 versus 5+21% after placebo. The subclass of the large thrombi (=7% of all platelets/thrombi but incorporating >90% of the platelet mass) was much stronger affected by the DT-TX 30 treatment: the mean area was reduced by 61+P7% after 25rag, 69+20% after 50mg, 78_+9% after 100mg, 53+25% after 200mg and 71_+8% after 400mg DT-TX 30 versus -16+40% after placebo.
In the presence of cells of the vessel wall (SMC) the overall thrombus formation was reduced by up to 42+21% after only 25 mg, 36+31% after 50mg, 59+_20% after 100mg, 72_+5% after 200rag and 81-+6% after 400 mg DT-TX 30 versus 2+_12% after placebo. In summary, DT-TX 30 showed a unique antithrombetic profile of selectively inhibiting the formation of large thrombi and cooperating with vascular smooth muscle cells in man ex vivo. DT-TX 30, a molecule combining potent and specific th romboxane synthetase inhibition with prostaglandin endoperoxide/thromboxane A 2 receptor antagonism, has been examined in healthy male subjects. Collagen-induced platelet aggregation in platelet rich plasma prepared from venous blood was measu red photometrically before and up to 24 hours after a single oral dose of 25, 50,100, 200 or 400 mg DT-TX 30 in a placebo-controlled, double-blind study. Platelet aggregation was induced in the ex vivo samples by collagen in concentrations between 0.5 and 10 p.g/ml to evaluate platelet aggregation in relation to the strength of the proaggregatory stimulus. The ECs0, i.e. the concentration of collagen required for a half-maximal aggregatory response (defined as the maximal change of the optical density), was determined.
In the placebo-treated control group, the mean ECso was 365+55 ng/ml collagen (+ SE; n=10) before treatment. It then varied between 362+41 and 417+_83 ng/ml collagen after treatment. The'ratio of the post-to the individual pre-treatment ECso values was 1.08 _+0.10 (n=10) at 0.5 h, 1.05_+0.11 at lh, 1.13_+0.14 at 2 h, 1.14-0.20 at 4 h, 1.07+ 0.07 at 8 h and 1.02+0.06 at 24 h. This indicates that the sensitivity of the platelets to collagen was not affected by the placebo treatment.
Oral treatment with DT-TX 30, however, strongly inhibited the aggregatory response of the platelets to collagen stimulation. The ECs0-ratio was increased to a maximum of 4.5_+0.85 (1 h p.a.; n=6) by 25 mg, 8.0-+1.9 (1 h p.a.; n=6) by 50 mg, 9.9-Z_1,6 (0.5 h p.a.; n=6) by 100 rag, 11.1+1.9 (0.5 h p.a.; n=5) by 200 mg and 22.7+4.4 ( 2 h p.a.; n=6) by 400 mg DT-TX 30. A substantial inhibition of collagen-induced platelet aggregation was observed still 8 h after the administration (ECso-ratio of 3.8+0.6 (n=6) for 100 mg and 7.8+1.3 (n=6) for 400 mg DT-TX 30 The detection of endogenous opioids suggested the opinion that in case of the presence in the organism of a receptor for an exogenous substance there is probably a similar endogenous substance.The occurrence in the blood of persons, who were not treated with cardiac glycosides, of endogenous digoxin-like or ouabain-like [actors confirms that opinion. In our study we took up the research of other drug-like [actors in the blood serum of healthy people.
In two hundered and twenty-five healthy volunteers (llOm,ll5f) non-smokers not receiving any treatment before or during the test and aged between IB and49 y(mean age 36y) the occurrence of drug-like [actors in blood serum was studied.The examinations were carried out with the use of the fluorescence-polarization-immunoassay (FPIA)-TDAbbott. Th e presence of the following endogenous drug-like fOctors in the blood serum was evaluated: quinidine,phenytoin, earbamazepine,theophylline, cyclosporineand gentamicin.
The The acetylation and oxidation phenotypes were studied in 448 healthy volunteers (235m, 213[) aged between iB and 46 years (mean 36y) in the Wielkopolska region in Poland.
The acetylation phenotype was studied with the use of sulphadimidine which was given in a dose of 44 mg/kg b.w. per os.Sulphadimidine was determined by a spectrophotometric method.The border value of M.R. was 75~ in urine.
The oxidation phenotype was studied with the use of sparteine which was given in a dose of 1,5 mg/kg b.w.per De. Sparteine was determined by the Gas Chromatographic method in urine. If M~ was 20 <HR4340 these are values for intensive metabolism, if MR was 0,22<MR(12 these are values for poor metabolism.
The determinated phenotypes were bimodally distributed. Our studies have short that 259 healthy volunteers (57.8~) were slow and 189 (42,2~) were fast metabolizers. Intensive oxidation phenotype could be ascertained in 423 volunteers (94,4~) and poor oxidation phenotype in 25 volunteers (5,6~).
These findings are comparable with the values typical for the Caucasian population. The genes coding for rapid acety!ation were present in 37.5 % of the cases, genes coding for slow acetylation were detected in 62.5 %. The frequency of specific NAT2 alleles were: R1, 20.7 %; R2, 1.2 %; Sla, 30.4 %; Slb, 3.1 %; Slc, 6.3 %; S2, 34.9 %; S3, 1.4 %; and S4, 2.0 %. There was no mutation found at 191 nt. In 166 cases (94.3 %) we have stated NAT2 genoand phenotype concordance, but in 10 cases (5.7 %), genotype and phenotype deviated from each other. Seven individuals were genotyped as SlaS2, one as SlaSle, and one as SlaS4 but were phenotypically rapid acetylators. One child was genotyped as R1 S 1 a but proved a slow acetylator.
We can confirm that in about 94 % NAT2 genotyping allows to properly predict NAT2 phenotype. Discrepancies may derive, i. a., from yet unknown mutations which we try to detect by DNA-sequencing. Several studies demonstrated that cardiac glycosides reduce diameter of epicardial coronary arteries. In patients (FFS) with coronary artery disease (CAD) this vasoconstrictive side effect of glycosides may cause ischemic complications in the presence ot high-grade stenoses. This study evaluated quantitatively the effect of an i.v. injection of digoxin on diameter of epicardial coronary arteries in 20 PTS with CAD. Eleven grs (group 1) were treated with aspirin 100mg/d, nine Frs (group 2) were treated with aspirin and 10rag nisoldipin 2 hours prior to angiography. Coronary angiograms were taken in identical projections before (0) and 5,10,15 and 30 minutes after i.v. injection of 0.8mg digoxin, at 35 rain 0.ling of nitroglycerin (NTG) was given. The mean diameters of normal segments and the minimum diameters of stenoses were analysed with CMS (Medis, Leiden). A total of 149 normal and 28 stenotic segments were analysed. (1 -(4-cyclohexylureido-phenoxy)-2-hydroxy-3 -tert.-butylaminopropan; AWD, Dresden) is frequently used as a cardioselective g-adrenoceptor antagonist. Talinolol metabolites in urine were detected by HPLC and GC/MS with previously characterized reference compounds and were quantified by HPLC with a normal phase silica column (Oertel et al., Br. J. Clin. Pharmacol. 37 (1994) 496) . Less than one per cent of administered dose was recovered in urine as bydroxylated talinolol. Other metabolites could be excluded. In serum after therapeutic doses talinolol metabolites were not traceable. However, in a suicidal patient with a parent compound serum concentration of 1400 ng/ml (manifold higher as after usual therapeutic dose) two hydroxy metabolites at concentrations near the detection limit (10 ng/ml) were found. Obviously only a small amount of the talinolol dose is metabolized in human. In this study the relation between structure, polarity and urinary recovery of the metabolites was examined. Four different isomers of mono-hydroxylated talinolol were identified in urine of volunteers after a single dose of talinolol. Eight isomers are possible: six hydroxy-cyclohexyl-compounds and two hydroxy-phenoxy-compounds. There was a low degree of specificity of biotransformation seen with respect to the point of attack on the cyelohexyl ring. Hydroxylation of the phenyl ring could be excluded in human. Using HPLC methods very small quantities of reference compounds are sufficient to estimate and compare the polarity and hydrophily of similar compounds. Long retention times in a normal phase system and short retention times in a reversed phase (RP) system are found for polar and hydropbilic compounds. The shortest retention times of all hydroxylated talinolol compounds in the normal phase system as well as the longest retention times in the RP system were found for the main metabolites 4-trans-and 3-cis-hydroxycyclohexyl-talinolol. Accordingly, the main metabolites are the most polar and hydrophilic mono-hydroxylated talinolol isomers. Lysine Clonixinate is a non-steroidal antiinflarnmatory drug with marked analgesic effects. It is used for treatment of acute pain such as postoperative, dental or menstrual pain. We have determined the biosynthesis of thromboxane (TX)B z and prostaglandin (PG)F2~ in clotting whole blood ex vivo as well as collagen-induced platelet aggregation before and 0.25, 0.5 (only TXB 2 and PGF2,~ biosynthesis), 1, 2.5, 6, 24 and 48 hours after oral intake of 125 mg Lysine Clonixinate. The results were compared with data obtained after oral intake of 500 mg acetylsalicylic acid (ASA). While both TXB 2 and PGF2,~ biosynthesis measured radioimmunologically were inhibited significantly (p<0,05 and p<0.01, respectively) 2.5 hours, but not 6 hours after Lysine Clonixinate, inhibition by ASA was much greater and still highly significant (p<0,01) after 48 hours. The mean concentrations of Lysine Clonixinate and of ASA inhibiting TXB 2 biosynthesis in vitro by 50% (ECs0) were 3.2 + 0.5 ~tM and 6.2 _+ 0.9 gM, respectively. Aggregation of 0.5 ml aliquots of platelet-rich plasma induced by 1 gg/ml collagen was inhibited by Lysine Clonixinate significantly (p<0.01), but not completely for up to 24 hours, while aggregation induced by 3 gg/ml collagen was inhibited for up to 6 hours only (p<0.01). Platelet aggregation induced by both collagen concentrations was inhibited by ASA almost completely (p<0.01) for at least 48 hours. The ECs0 for in vitro inhibition of submaximal collageff-induced platelet aggregation was 59 + 16 btM for Lysine Clonixinate and 97 + 21 laM for ASA. It remains to be investigated, whether other mechanisms than inhibition of cyclooxygenase contribute to the analgesic activity of Lysine Clonixinate. The profile of side effects including only moderate inhibition of platelet function by Lysine Clonixinate as compared to ASA might be an advantage with regard to its use as an analgesic. Increased cell proliferation induced by ras-oncogenes is mediated by growth factors. Growth factors bind to cell membrane surface receptors and activate tyrosine kinases leading to protein phosphorylation. This triggers posttranslational modification of the function of low molecular mass GTP binding Ras proteins, e.g. p21ras, including heterotrimetric G proteins. Th~se proteins carry a C-terminal amino acid sequence, CAAX where C is cysteine, which is the target of isoprenylation by famesyl protein transferases (FPPTases) and geranyl-geranyl protein transferases (GGPTases). The amino acids of this sequence determine whether the Ras protein is substrate for FPTases or GGPTases. This biochemical pathway is related to mevalonate metabolism, therefore, cholesterol biosynthesis shares several steps with isoprenylation. The active compounds include a series of isoprenoid inter-mediates, such as geranyl pyrophosphate (C-10), farnesyl pyrophosphate (FPP, C-15) and geranyl-geranyl pyrophosphate (GGPP, which are critical for cell proliferation. Inhibitors of isoprenylation may (i) compete with FPP to its binding site on the alpha subunit of the enzyme, (ii) inhibit the Zn protease of FPTase beta subunit, and (iii) interfere with the binding of the CAAX peptide to its binding site on the beta subunit. The inhibitors include microbial products like manumycin, gliotoxin, acetylgliotoxin and pepticin-namins, FPP analogues, tetrapeptides and related peptidomimetics that may compete for the CAAX sequence, products of plant origin like limonene as well as synthetic compounds. All these compounds have been known to retard cell proliferation, and their effect can be abolished by mevalonic acid. Inhibitors of HMG-CoA reductase, such as lovastatin, which have been developed as antihypeflipidemic drugs, may also effective as anticancer agents. The recognition of the importance of mevalonate metabolism in cancerogenesis provides possibility to test simple chemical comp6unds against tumor growth, and gives promise for pharmacological exploitation of inhibitors of isoprenylation and HMG-CoA reductase inhibitors for cancer chemotherapy.
A76 HEMODYNAMIC, RENAL AND ENDOCRINE EFFECTS OF DOPAMINE AND EPININE IN HEALTHY VOLUNTEERS
U.Potler, K.POnicke, M.E]ter-Schulz*), A.Daul*), F.JockenhOvel*) and O.-E.Brodde, Institute of Pharmacology, University of Halle, and *)Departm. of Internal Medicine, University of Essen, Germany Dopamine (DA) and epinine (EPI, the active metabolite of ibopamine) are DA-and ~-and ~-adrenergic receptor (R) agonists. To study whether DA-R mediated effects can be separated from ~-and ~-AR effects we assessed in 10 male volunteers effects of i.v. DA and EPI (0.5; 1.0; 2.0 and 4.0 ~g/kg/min for 15 min each) on changes in serum prolactin (PRL, DA-R mediated), blood pressure (P) and heart rate (HR, ~-and ~-AR mediated), natriuresis (urinary excretion of sodium), diuresis (urine flow rate) and plasma noradrenaline (NA) levels. In the 0.5 and 1.0 ~g doses DA and EPI did not affect Psyst, Pdiast and HR, but significantly decreased PRL (DA: from 4.2±0.5 to 2.7±0.4 ng/ml; EPI: from 6.3±I.I to 4.4±0.8 ng/ml, p<O.01). In the 4~g dose DA and EPI increased Psyst by 20mmHg, Pdiast by 4 and 8mmHg, and HR by 8 and 11 beats/min but further decreased PRL. In addition, both DA and EPI significantIy increased diuresis and natriuresis; in contrast, only DA, but not EPI, dose-dependently increased plasma NA Ievels, an effect that was not inhibited by ~-AR antagonists. We conclude that in 0.5 and 1.0 ~g doses (plasma levels of 20-70 nmol/1) OA and EPl act only at DA-R. In higher doses, however, DA and EPI can activate ~-and ~-AR whereby EPI has a stronger ~-AR component than DA. Moreover, part of DA-effects are indirect via release of endogenous NA whereas EPl-effects do obviously not include an indirect component.
EFFECT OF LOW DOSE CICLETAN]N ON PROSTACYCLIN SYNTHESIS AND BLOOD PRESSURE IN HYPERTENSIVE PATIENTS
J. Raderrnacher, R.MLiller-Bartels, F. Barrels, H. Baurngarten, K. Thon, D. Tsikas and J.C. Fr61ich, 20 patients with essential hypertension were Ireated with cicletanin (100 rag/d) for 12 weeks. Compliance was verified by measuring urinary cicletanin excretion. Before entering the study anti_hypertensive medication had been withdrawn for at least 2 weeks (wash out phase). The study was preceeded by a placabo phase of 1 week duration. Blood pressure measurements and urine collections for measurements of 2,3dinor-6-ketoProstaglandin F1 a (a stable prostacyclin metabolite) were performed at the start and end of placebo phase, atter 1 week of treatment with cicletanin and in monthly intervalls thereafter. Cicletanin decreased systolic and diastolic blood pressure, the effect becoming significant at 4 weeks. Urinary excretion of the prostacyclin metabolite 2,3dinor-6 keto PGFla.increased by 21%. Hypertensive patients and control subjects (n=13; 2,3dinor-6-keto-PGFla: 120+19 pg/rnl] did not differ significantly in urinary excretion of 2,3dinor-6 keto PGF1 ct. Neither systolic nor diastolic blood pressure showed a significant correlation with 2,3dinor-6 keto-PGF1 alpha excretion (systolic BP: R--0,12, p--0,2l; diastolic BP: R=0,0007, p=l,0).
These data show that cicletanin is effective in reducing blood pressure. Increased prostacyclin production is probably not responsible for the observed reduction of blood pressure.
Institute of Clinical Pharmacology and Dept. of Nephrology; Hannover Medical School, Konstanty Gutschow Str. 8, 30625 Hannover, Germany
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CLINICAL-PHARMACOLOGICAL ASPECTS OF THE NICERGO-LINE BIOAVAILABILITY H. Rameis
In the past the realization of trials on the pharmacokinetics of Nicergoline in human beings break down according to analytical difficulties. From animal studies with labelled compounds it is known, that Nicergoline is rapidly absorbed from the gastrointestinal tract and two main metabolites (MDL, I-MMDL) can be detected.The mean elimination half-life for Nicergoline is given with 2,5 h, for MDL 12-17 h and for I-MMDL with 4-6 h. The compound is excreted mainly by the kidney. Due to known problems of the application of labelled drugs in human beings there are two approaches for the determination of these compounds: first the detection by monoclonal antibodies by using a RIA-method, secondly a HPLC-analysis. Although there are promising in-vitro results of the immunological method, quantitative analyses of serum samples show deceptive results. The HPLCassay reveales that in human serum samples after oral administration of Nicergoline only the metabolites MDL and I-MMDL can be detected. Further analytical development lower the limit of detection which should be i/i0 of c~x. With an improved HPLC-method it will be demonstrated that only the measurement of the metabolite MDL is suitable to give sufficient results in pharmacokinetic trials and in studies on bioavailability with formulations of Nicergoline. Antiplatelet treatment with aspirin is well established as secondary prophylaxis after a transient ischemic attack or minor ischemic stroke, but the effect of aspirin treatment on the course of carotid atheroselerosis is unknown. We tried to investigate the effect of aspirin on the initial stages of carotid atherosc}erosis.
Patients were recruited from a prospective, randomized, double blind clinical trial to compare two doses of aspirin (900 mg vs 50 mg claity) with respect to restenoses after lower limb angJoplasty. Of the 383 patients admitted to the angioplasty trial, 27 patients showing 104 small carotid atheroma (<50% lumen narrowing) were examined at entry and after 1 year of aspirin treatment using a high-resolution ultrasound duplex system. Disease progression and regression were defined by a change of maximal plaque area (as measured by longitudinal ultrasound sections) of more than 2 standard deviations of the method.
The change in plaque area was significantly different for the treatment groups: average plaque size remained'unchanged after treatment with 900 mg aspirin daily but increased markedly after treatment with 50 mg aspirin daily (p = 0.011). There were significantly more lesions in the 50-mg group showing progression than in the 900-mg group (23 plaques [47%] vs 13 plaques [24%], p = 0.025). Ultrasonic disappearance of a lesion was observed only in the 900-mg group in 9 cases (7 soft plaques, 2 ulcerative plaques, p = 0.018). The 6 patients on 50 mg aspirin who continued smoking during the study showed significantly more progression as compared to the 7 non-smokers in the 50-mg group (17 plaques [59%] vs 6 plaques [30%], p = 0.038).
The results of our study indicate that aspirin treatment slows carotid plaque growth in a dose-dependent fashion, with a dose of 900 mg daily more efficient than 50 mg a day. Gentamicin is frequently applied in neonatal patients for the treatment of severe infections. The use is associated with high incidences of oto-and nephrotoxicity. Ototoxicity occurs in 1-1.5 % of the treated patients. It can be avoided, if the trough levels remain under 2 p.g/ml between the administered doses. If the nephrotoxic effect, which occurs in 2-10 % of the treated patients, can also be reduced under these circumstances is not yet clear. Recently it has been suggested to administer gentamicin only once daily in order reach the desired trough levels. This applies especially to children, in which the terminal half-life can be prolonged to approximately 9 hours. This dosage regimen assures a sufficient effectivity due to the marked postantibiotic effect, but should reduce the incidence of the toxic effects.
In order to test this hypothesis we perform a case-control study with neonatal children treated with gentamicin. The cases of nephrotoxicity during the previous 12 months are identified from the hospital records. For these patients the plasma level time curves are obtained with the use of a population based pharmacokinetics programme, which considers the measured plasma concentrations and the administered doses. Plasma concentrations were measured routinely in the process of therapeutic drug monitoring. From these curves the duration of times with concentrations lower than 2 p.g/ml during the last 3 days prior to the diagnosis are estimated. For the cases matched controls were identified according to age, age of gestation and other factors affecting the renal function e.g. comedication. Different analyses are carried out according to the definition of exposure. The results wiIJ be discussed with regards to the modification of the dosage schedule for gentamicin and the application of population kinetics in order to reduce the adverse effects. Economic evaluation of drug therapy is an important task of Clinical Pharmacology. Drug costs amount to a relatively small percentage of total health care costs. Some drugs may help to avoid more expensive therapeutic procedures. Drugs with small therapeutic ratio need e therapeutic drug monitoring (TDM) to optimize therapeutic results and to avoid side effects. TDM may enhance the costs of drug therapy and the question arises, whether the additional costs are justified from the economic point of view. The aim of the study was to investigate the effectiveness of theophylline TDM in chronic obstructive pulmonary disease.
Methods: 30 outpatients suffering from chronic obstructive pu[monary disease and receiving theophylline as a basic medication were included in this study. During the one-year observation period the parameters of pulmonary function were examined four times (1 st, 3rd, 6th and 12th month) by the same physician and theophylline trough levels were estimated to individualize the dosage. The clinical outcome was assessed by intraindividual comparison.
Results: Impaired parameters of pulmonary function were improved. Hospital admissions were reduced. During the one-year observation period 4 out of 30 patients had 6 hospital admissions with totally 64 days. Under the conditions of theophylline therapy without TDM during the year before 7 of them had 13 hospital admissions with 197 days of stay in hospital.
Discussion: The results agree with a previous study on inpatients. There it was observed, that parameters of pulmonary function significantly were improved due to TDM-supported theophy[line therapy in comparison to a group receiving theophylline without TDM. Despite the additional costs thaopylline TDM contributes not only to improved clinical outcome but also to decreased costs for the care of patients with chronic obstructive pulmonary disease. In cancer treatment arterial blood flow reduction by embolisation followed by intra-artedal chemotherapy may be advantageous by achieving high and prolonged drug concentrations in the tumor and lower systemic drug exposure. Pharmacokinetics of mitomycin-C (MMC) were investigated in 4 colorectal cancer patients (body weight: 55-92 kg) with liver metastases undergoing chemoembolisation. After hepatic artery branch catheterization and microspheres injection (Polyvinylalcobel, circumference: 150-250 pro, ITC-Contour Rehaforum Medical) 20 mg MMC dissolved in 20 ml physiological NaCI solution were infused in 5-8 rain, followed by Ethiblock application. Serum MMC-concentrations were determined from peripheral venous blood samples by reverse-phase HPLCsystem with ultraviolet detection (C18-column, Elution: phosphate-buffer (0.01M, pH:6.5)) : methanol, V:V=70:30, 365 nm). Pharmacokinetic parameters were computed using non-compartmental or two-compartment model analysis assuming linear kinetics (Top Fit 2.0 Software). Results: On the average, maximum serum concentrations were observed at Tmax = 7.7 rain following the beginning of MMC-infusion and amounted to Cmax = 1095 ng/ml (range: 562-1790 ng/ml). Mean steady state distribution volume was 0.56 I/kg with a central compartment volume of 0.22 I/kg. Concentration-time curves could be descnbed by a distributional phase (T1/2 = 8.5 min) followed by a terminal elimination phase (]'1/2 = 72.4 min). Mean total clearance amounted to 8.6 ml/min.kg. The area under the concentration time curve was 33 pg.m1-1 .min. Conclusion: Pharmacokinetic parameters for MMC-disposition in this study do not substantially differ from those reported for similar MMC-amounts administered as intravenous bolus. Systemic MMC exposure does not seem to be reduced following the embolisation procedure used compared to intravenous application. Pseudocholinesterase-activity (PChE) is an important determinant of the elimination kinetics of drugs like mivacudum. Therefore, the time course of PChE was investigated in 16 patients undergoing cardiosurgery with cardiopulmonary bypass (CPB) in normo-or hypothermia. Anesthesia was induced and maintained with midazolam, propofol and fentanyl using mivacurium as a muscle relaxant. By starting CPB, 2 I of pdming fluid were added to circulation volume. From collected blood samples, PChE (U/I) was determined photometrically according to EIIman (1961) (butyrylthiocholine, dithiobisnitrobenzoate, 405 nm, pH=7.0, 37Oc) . Total plasma protein concentration (g%) was measured according to Lowry, and the specific PChE was calculated as the quotient of PChE and protein concentration (U/g). Serum hepadn-activity was determined in 4 patients (Berichreme Heparin test kit). Moreover, the influence of hepadn and aprotinin, both contained in the CPB pdming solution, on PChE in vitro was examined using fresh serum from healthy volunteers (n=3). Results: The induction of anesthesia had no significant influence on PChE or protein concentration (p>0.05). CPB induced a significant decrease of PChE (-37%)(p<0.05) and protein concentration (-24%)(p<0.05) and a less pronounced numedcal reduction the specific PChE (-15%)(p>0.05). The reduction of PChE and protein concentration was not significantly affected by ending CPB (p>0.05), and the values remained low over the remaining operation time. There was no significant difference in PChE, measured at 37°C in vitro, or protein concentration between the normothermic and hypothermic group (p>0.05). Furthermore, there was no correlation between serum hepadn-activity and PChE reduction. PChE in the plasma of healthy volunteers was not significantly affected by either hepadn up to 100 U/ml or apretinin up to 10 000 U/ml (p>0.05). Conclusion: (1) The concentration of the antitumor antibiotic mitomycin C (MMC), used in ophtalmic surgery for its antiproliferative effects, was measured in the aqueous humor of 7 glaucoma patients undergoing trabeculectomy. Sponges soaked with MMC-solution (100 ul of MMC-solution 0.2 mg/ml: 20 rag) were applied intraoperatively under the scleral flap for 5 rain. 100 to 200 ul of aqueous humor Were drawn with a needle 10 min following the end of topical MMC-treatment. Samples were assayed for MMC using a reverse-phase HPLC-system with ultraviolet detection (C18-column, Elution: Phosphate-buffer (0.01M, pH:6.5):methanol, V:V = 70:30 , 365 nm). Swabs were extracted in phosphatebuffer (0.1M, pH:7.0) before HPLC-analysis. External calibration was used for MMC quantitetion. Quantitation limit was 10 ng/ml. In all aqueous humor samples MMC-concentration was below 10 ng/ml. MMC in the swabs amounted to 37 % of the MMC amount applied. Conclusion: After intraoperetive topical application, MMC concentration in the aqueous humor of patients is very low. The substantial loss of MMC from the swabs used for the topical MMC-treatment suggests (1) rapid systemic absorption of MMC and/or (2) a loss through irngation of the operative field following topical MMC-application. Due to runaway costs of the national health service which are reflected as well in growing expenditures for drugs at the University Hospital of Jena investigation of indication related drug administration patterns becomes more and more interesting. This holds especially true for intensive care units (ITU's) which are determined by similar high costs for technical equipment as for drugs (1) although any economical considerations seem to be questionable due to ethical reasons (2). Over a 4 month period indication related drug administrations of 2 surgical ITU's of the University Hospital Jena have been recorded and analyzed by using a PC-notebook. Total expenditures for all 465 included patients add up to DM 1.144.773 regarding these drugs and blood products which caused 80% of total costs in 1993. The 10 leading substances ( Antithrombin Ill, Human Albumin 20 %, Prothrembine complex, ...) represent 67 % of total costs including blood products, antibiotics and Ig M endched intravenous immunglobine. Therefore the indication of particulary these drugs became mere interesting for further investigations. Already during the study actual discussions with the treating medical staff have been made leading to new developed therapy recommendations. Providing same high standard of medical treatment a remarkable cost saving of some drugs by more cdtical and purposeful use could already be achieved as a first result. However, the results of the study underline impressivly the benefit of such investigations for improvement of drug treatment. The simple replacement of expensive drugs ( e.g. prothrembine complex ) by higher quantities of cheaper ones of the same indication group ( e.g. fresh frozen plasma (3)) does not necessarily mean less expenditures in all cases but may cause unsiderable side effects.
( The improvement of pain and swelling conditions by means of drugs is an important method of achieving an enhanced perioperative quality of life in cases of dentoalveolar surgery. In 5 prospective, randomised, double-blind studies the influence of various concentrations of local anaesthetics and accompanying analgesic and antioedematons drugs was investigated in the case of osteotoimes. All of the studies were carded out according to a standardised study procedure. A comparison of the local anaesthetics articaine 4 % mad articaine 2 % (Study 1) demonstrated the superior effect of articaiue 4% with respect to onset relief on pain, period of effectiveness and ischaemia. Recordings of the cheek swelling in the remaining studies were made both sonographically and with tape measurement, while the documentation of the pain was carried out by means of visual analogue scales on the day of operation and on the first and third post-operative days. Tile perioperative, exculsive administration of 2x6 mg Dexamethasone (Study 2) resulted in a significant reduction in the swelling (58 %) while the exclusive administration of 3x400 mg lbuprofen (Study 3) was accompained by a marked decrease in pain (64%) but no significant reduction of swelling in comparison to the placebo group. The combination of 3x400 mg Ibuprofen und 32 mg Methylprednisolone (Study 4) yielded a decrease in pain of 67.7% and a reduction in swelling of 58%. A cdmparison between a mono-drug Ibuprofen and a combination drug ASS/Paracetamol (Study 5) resulted in no significant difference in the reduction of swelling and pain and therefore highlighted no advantages for the combined drug. A mono-drug should therefore be given priority as an analgesic. The combinatton of Ibuprofen und Methylprednisolone offers the greatest reduction in pain and swelling. Using the results of the randomised studies, a phased plan for a patietu-orietued, anti-inflammatory therapy to accompany dento-alveolar surgery is presented. In a placebo controlled study 20 patients with congestive heart failure (NYKA class II) were treated orally for seven days with i00 mg ibopamine t.i.d, i0 subjects had a normal renal function (mean inulin clearance (GFR) 91 ± 3,4 ml/min), i0 patients suffered from chronic renal insufficiency (GFR 36 ± 3,9 ml/min; X ± SEM). Pharmacokinetic parameters of epinine, the maximum plasma concentration, the time to reach maximum plasma concentration and the area under the curve from 0 to 6 hours were unaltered in impaired renal function when measured on the first or on the seventh treatment day. However plasma concentrations in both groups were significantly higher on the first treatment day than after one week of ibopamine administration. In this context antipyrine clearance as a parameter of oxidative liver metabolism which might have been induced by ibopamine revealed no differences between placebo and ibopamine values. In conclusion kinetic and dynamic behaviour of ibopamine was not altered by impaired renal function. (Kisiel et al 1977) . Its concentration in normal plasma is 2-6 lag/m[ I-IPC's biological importance became evident when a congenital Protein C deficiency, which results in difficult recurrent thromboembolic diseases was discovered (Griffin eta/1981) .
The recognition of a congenital HPC deficiency, as wall as the connection between acquired Protein C deficiency and the appearance of thromboembolic complications by means of highly accurate and sensitive ascertained methods is therefore of great practical importance for the clinic.
Murine monoclonal antibodies (moAbs) against HPC were formed. Antibody producing hybridomas were tested by an ,,indirect ELISA" against soluble antigens. The plates were coated with purified HPC up to 50 ng/1001al. The peroxydase-system was used to identify antibodies The antibodies were tested with the remaining Vitamin K-dependent proteins for cross-reactivity, as well as with HPC deficiency plasma for disturbances by other plasma proteins. The above described experiment represents a sensitive and specific method for measuring the HPC concentration with moAbs. Assessment of local drug absorption differences ("absorption window") in the human gastrointestinal tract is relevant for the development of prolonged release preparations and for the prediction of possible absorption changes by modification of gastrointestinal motility. Current methods are either invasive and expensive (catheterization of the intestinum, HF-capsule method) or do not deliver the drug to a precisely defined localization. We evaluated the delay of drug release from tablets coated with methacrylic acid copolymer dissolving at different pH values as an alternative method. Three coated preparations of caffeine tablets (onset of drug release in in vitro tests at pH 5.5, 6.0 and 7.0) and an uncoated tablet (control) were given to six healthy male volunteers in a randomized order. Caffeine was used because of its rapid and complete absorption and good tolerability. The relative bioavailibility for the coated preparations did not differ from the reference, suggesting complete release of caffeine. All coatings delayed caffeine absorption onset. The Tlag for the pH 5.5 preparation suggests that release started immediately after the tablet had left the stomach. The mean delay of 2.1 h for the pH 6.0 coating was highly reproducible and should reflect small intestine release. The pH 7.0 coating delayed absorption to the highest extent, however the drug was probably released before the colon was reached. There is evidence that nitric oxide (NO) plays a role in cardiovascular disease like hypertension, myocardial ischemia and septic cardiomyopath.y. NO stimulates the guanylyl cyclase leading to an increase m cGMP content We investigated by immunoblotting the expression of the inducible nitric oxide synthase (iNOS) in left ventricular myocardium from failing human hearts due to idiopathic dilative cardiomyopathy (IDC, n=10), ischemic cardiomyopathy (ICM, n=7), Beeker muscular dystrophy (n=2) and sepsis (SH, n=3) compared to non-failing human hearts (NF, n=4). Cytokine-stimulated mouse macrophages were used as positive controls SDS-polyacrylamide gel electrophoresis (7.5 %) was perfomed with homogenates of left ventricular myocardium and mouse macrophages respectively. Proteins were detected by enhanced chemiluminescence using a mouse monoclnal antibody raised against iNOS. Furthermore, we measured the cGMP content in these hearts by radioimmunoassy. A band at about 130 kDa was observed in two out of three hearts from patients with sepsis and in stimulated mouse macrophage~ No iNOS-protein expression was detected in either non-failing human hearts (n=4) or failing human hearts due to IDC, IHD or BMD. In ventricular tissue from patients with sepsis cGMP content was increased to 230% (72 + 17 fmol/mg ww, n=3) compared to non-failing hearts (100% or 31 + 6.9 fmol/mg ww, n=4). In left ventricular tissue tissue from patients with heart failure due to IDC, IHD and BMD cGMP content did not differ from that in non-failing hearts. It is concluded that an enhanced iNOS protein expression may play a role in endotoxin shock, but is unlikely to be involved in the pathophysiology of end-stage heart failure due to IDC, IHD and BMD. (Supported by the DFG.) Nitric oxide (NO) has been shown to be a major messenger molecule regulating blood vessel dilatation, platelet aggregation and serving as central and peripheral neurotransmitter; furthermore NO is a crucial mediator of macrophage cytotoxicity. NO production can be assessed reliably by determination of its main metabolites nitrite and nitrate in serum, reflecting NO synthesis at the time of sampling, or in 24 h urine, reflecting daily NO synthesis. Farrell et ai. (Ann Rheum Dis 1992; 51:1219) recently reported elevated serum levels of nitrite in patients with rheumatoid arthritis (RA). We report here total body nitrate production and the effect of prednisolone in patients with RA. Nitrate excretion in 24 h urines of 10 patients with RA as defined by the 1987 revised criteria of the American Rheumatism Association was measured by gas chromatography at 2 times: First before start of a antiinflammatory therapy with prednisolone, when the patients had high inflammatory activity as indicated by mean CRP serum concentrations of 71 + SD 61 mg/I and elevated ESR with a mean of 62 ]:28 after 1 hour. Secondly 2-4 weeks after start of prednisolone therapy in a dosage of 0.5 mg/kg body weight, when the patients showed clinical and biochemical improvement (CRP 6 + 5 mg/I, p<0.05, ESG 32 + 17, p<0.001, two-tailed, paired t-test). For comparison 24 h urines from 18 healthy volunteers were obtained. Before start of predniselone therapy the urinary nitrate excretion in patients with RA (mean 223 + SD 126 p.mol/mmol creatinine) was more than twofold higher (p<0.001, twoAailed unpaired t-test) than in healthy volunteers (83 + 63 ~tmol/mmol creatinine). The urinary nitrate excretion decreased significantly (p<0.001, two-tailed, paired t-test) to 162 + 83 i.tmol/mmol creatinine under therapy with prednisolone, when inflammatory activity was reduced considerably. Despite the decrease the urinary nitrate excretion was still twc, fold higher (p<0.05, two-tailed, unpaired t-test) in patients with RA than in the control group. Our data suggest that the endogenous NO production is enhanced in patients with RA. Furthermore the results indicate that this elevated NO synthesis could be reduced in accordance with suppression of systemic inflammation by prednisolone therapy. But now as ever the physicians are entitled to prescribe drugs which have to prepare in a pharmacy for a particular patient. Little information is available on the frequency and patterns of these prescriptions. We had occasion to analyse the prescriptions of drugs which were prepared in 6 pharmacies in North Thuringia (East Germany) from October to December 1993 at the expense of a large health insurance company (Allgemeine Ortskrankenkasse). The selected pharmacies are loealised in 6 cities. We found 2172 prescriptions of drugs made up in pharmacies among a total number of 58472 reviewed drug prescriptions. This is 3.7 % of the total. Most of these prescriptions were performed by dermatologists (56.6 %), general practitioners (21.9 %), paediatrists (7.9 %) and otolaryngologists (4. 1%).
According to this, the most frequently prescribed groups of drugs were dermatics
Introduction and Methods
Enteric eoated tablets with 100 nag and 300 nag acetylsalicylic acid (ASA) have been developed wluch should avoid the known gastrointestinal adverse events by a controlled drug release mainly in the duodenum after having passed the stomach. A 4-way cross-over study in 24 healthy male subjects, aged from 19-39 years, was conducted to investigate the pharmacokinetics, bioavailability, safety, and tolerance of ASA and its metabolites salicylic acid and salicylurie acid following enteric coated tablets in comparison with plain tablets. ASA and its metabolites were determined by a sensitive, specific, and validated HPLC method. Pharmacokinetic parameters were determined by non-compartreental analysis. Bioequivalence was assessed by 90% confidence intervals. Following the admimstration of enteric coated tablets, a delayed absorption can be observed for both the 100mg dose and the 300rag dose. This is likely due to a delayed release of the active substance from the enteric-coated tablets in the small intestine aRer gastric passage. Considering the mean residence times (MRT), there is a difference of at least 2.8 h following the enteric coated tablets compared to the plain tablets for ASA and the two metabolites measured• This difference represents the sum of residence time in the stomach plus the time needed to destroy the coating of the tablet when it left the stomach• In general, the maximum observed concentrations of both enteric coated formulations occurred 3-6 h post dose.
PHARMACOKINETICS OF ANTI-HBS AFTER AN INTRA-VENOUS INFUSION OF IMMUNOGLOBULIN G (BT 507) IN 12 HEALTHY MALE VOLUNTEERS P. Thiirmann, Ch. Sonnenburg-Chatzopoulos
The pharmacokinetics of a novel immunoglobulin G (lgG) preparation (BT507, Biotest, Dreieich, FRG) have been determined in 12 healthy, male anti-HBs-negative volunteers. For this preparation only plasma from HIV-, HBV-and HCV-negative donors was used, the quality control for the product was in accordance with the EC-guideline for virus removal and inactivation procedures. Each volunteer received a single, intravenous infusion of 100ml BT507 containing 5g IgG and anti-HBs > 5,000 IU. Anti-HBs was used as a simply measurable and representative marker for the IgG. Blood samples for determination of anti-HBs (AUSAB EIA, Abbott, FRG) were drawn before and directly after the infusion, after 1,3,6,12 and 24 hours, on day 3,5,8,15,22, 29,43,57,71,85 and 99 . Additionally, total protein, IgG, IgA, IgM and C3/C4 complement were measured and blood hematology and clinical chemistry parameters determined. The phar~gacokinetic parameters of anti-HBs were calculated using the TOPFIT ~" PC program assuming a 2-compartment model. Pharmacoeconomic evaluations (PE) describe the relationship between a certain health care input (costs) for a defined treatment and the clinical outcome of patients measured in common natural units (e.g. blood pressure reduction in mmHg), quality of life (QoL) gained, lifes saved or even in money saved due to the improvement in patients functional status. This implies that the efficacy of a treatment has been measured and proven in clinical trials. In addition, in order to transfer data obtained in clinical trials to the clinical setting, an epidemiological database for diseases and eventually drug utiIization may be required. The evaluation of the efficacy depends on the disease to be treated or prevented and the mode of treatment. For acute, e.g. infectious diseases, the endpoint can be defined easily by the cure rate, but for PE the time (length of hospital stay) and other factors (e.g. no. of dally drug administrations) have to be considered. In the case of chronic diseases, e.g. hypertension or hypercholesterolaemia, surrogate endpoints (blood pressure or serum cholesterol reduction) and information on side effects may be acceptable for the approval, but cannot be used for a meaningful PE. The latter should include the endpoints of the disease, i.e. cardiovascular events (requiring hospitalisation and additional treatment) and mortality. Furthermore, the QoL has to be measured and considered for chronic treatment. Several questionaires have been developed to measure the overall QoL or the health related QoL. Especially the latter may be a more useful tool to detect mad quantify the impact of a treatment on QoL. Combining the clinical endpoint mortality and QoL by using QALYs (quality-adjusted lifeyears) may be a useful tool to determine the value and costs of a given drug treatment but cannot be applied to all treatments under all circumstances. Sorbitol was used as a model substance to investigate the dynamics of the initial distribution process following bolus intravenous injection of drugs. To avoid a priori assumptions on the existence of well-mixed compartments data analysis was based upon the concept of residence time density in a recirculatory system regarding the pulmonary and systemic circulation as subsystems. The inverse Gaussian distribution was used as an empirical model for the transit time distribution of sorbitol across the subsystems, Distribution kinetics was evaluated by the relative dispersion of transit (circulation) times. The distribution volumes calculated from the mean transit times were compared with the modelindependent estimate of the steady-state volume of distribution. Kinetic data and estimates of cardiac output were obtained from 10 patients after percutaneous transluminal coronary angioplasty. Each received a single 0.8 g iv bolus dose of sorbitol. Arterial blood samples were collected over 2 hours. While the disposition curve could be well fitted by a tri-exponential function the results indicate that distribution kinetics is also influenced by the transit time through the lungs, in contrast to the assumption of a wellmixed plasma pool underlying compartmental modelling. A significant correlation was found between estimated CL and cardiac output. This result reflects a linear dependence of hepatic perfusion on cardiac output in the observed range (CO between 4150 and 7248 ml/min). Karit@ "bu£ter" is used traditionally in West Afr%can Manding colture as a cosmetic to protect the skin against the.sun. Gas chromatography was used to analyze the ingredients of Karit@ butter from Guinea. We found 3% palmitic acid, 42% stearic acid, 42% oleic acid and 8% linoleic acid and 0.1% of other fatty acids with higher chain lengths like arachidonio acid. Some of these are essential fatty aclds (vitamine F). Furthermore Karit@ contains vitamine A and D as well as triterpene alcohols and phytosterines. An original extract was used to prepare a skin cream. This preparation was tested in 25 volunteers (18 women, 7 men; age 20-55 y.). The cream contained at least 50% Karit@, glycerol, emulsifiers and no preservative agent except for sorbic acid. 24 of the volunteers very well tolerated the cream and thought it effective. The skin became more tender and elastic. Good results were obtained when the volunteers suffered from very dry skin. Two of them who were known to be allergic against the most available skin creams had no problems in using our Karit8 cream. Pure Karit@ butter was used for four months to treat an African infant with neurodermitis. After this time the symptoms had markedly improved whereas previous therapy trials with other usual topical medicaments had been unsuccessful. These pre-studies had shown that dermatologic preparations containing Karit# may be a good alternative in the treatment of therapyreslstent skin diseases and may in some cases be able to replace eorticoid treatment. In bleeding time blood, r-hirudin and the heparin preparations significantly inhibited the formation of both TAT and F1+2. However, the inhibitory effect of r-hirudin on F1+2 generation was short-lived and weaker compared to UFH and LMWH and the TAT/F1+2 ratio was significantly lower after r-hirudin than both UFH and LMWH. Thus, in vivo when the coagulation system is in an activated state r-hirudin exerts its anticoagulant effects predominantly by inhibiting thrombin (lla), whereas UFH and LMWH are directed against both Xa and Ila. A different mode of action of UFH and LMWH was not detectable. In venous blood, r-hirudin caused a moderate reduction of TAT formation and an increase (at 1 hour) rather than decrease of F1+2 generation. Formation of TAT and F1+2 was suppressed at various time points following both UFH and LMWH. There was no difference in the TAT/F1+2 ratio after r-h[rudin and heparin. Thus, a predominant effect of rhirudin on Ila (as found in bleeding time blood) was not detectable in venous blood. In bleeding time blood, r-hirudin (but neither UFH nor LMWH) significantly inhibited ~-TG release. In contrast, both UFH and LMWH caused an increase of ~-TG 10 hours after hepadn application. Our observation of reduction of platelet function after r-hirudin compared to delayed platelet activation following UFH and LMWH suggests an advantage of r-h[rudin over heparin, especially in those clinical situations (such as arterial thromboembolism) where enhanced platelet activity has been shown to be of particular importance. The human cytochrome P450 isoform CYP1A2 determines the level of a variety of drugs metabolized by the enzyme, including caffeine (CA) and theophylline (TH). More than 50 compounds are potential or proven inhibitors of this enzyme. Some of them were reported to be substrates or inhibitors to CYP1A2 in vitro, ethers caused pharmacokinetic interactions with drugs metabolised by CYP1A2. We characterized a series of these compounds with.respect to their effect on CYP1A2 in human liver microsomes in relation to-published pharmacokinetic interactions in vivo. CYP1A2 activity in vitro was measured as CA 3-demethylation at the high affinity site in human liver microsomes, using 15 rain incubation at 37 °C with 125 -20001JM caffeine, an NADPH generating system, and inhibitor concentrations covering 1.5 orders of magnitude. Apparent Kr values were estimated using nonlinear regression analysis. For inhibitory effects on CYP1A2 activity in vivo, the absorbed oral dose causing 50 % reduction in CA or TH clearance (EDso) was estimated from all published interaction studies using the Emax model. 
